<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5372572</article-id><article-id pub-id-type="doi">10.3390/ijms18030556</article-id><article-id pub-id-type="publisher-id">ijms-18-00556</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia&#x02014;Implications for Vaccine Design</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rey-Jurado</surname><given-names>Emma</given-names></name><xref ref-type="aff" rid="af1-ijms-18-00556">1</xref></contrib><contrib contrib-type="author"><name><surname>Kalergis</surname><given-names>Alexis M.</given-names></name><xref ref-type="aff" rid="af1-ijms-18-00556">1</xref><xref ref-type="aff" rid="af2-ijms-18-00556">2</xref><xref rid="c1-ijms-18-00556" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Esposito</surname><given-names>Susanna</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-18-00556"><label>1</label>Millennium Institute on Immunology and Immunotherapy, Departamento de Gen&#x000e9;tica Molecular y Microbiolog&#x000ed;a, Facultad de Ciencias Biol&#x000f3;gicas, Pontificia Universidad Cat&#x000f3;lica de Chile, Santiago 8330644, Chile; <email>erey@bio.puc.cl</email></aff><aff id="af2-ijms-18-00556"><label>2</label>Departamento de Endocrinolog&#x000ed;a, Facultad de Medicina, Pontificia Universidad Cat&#x000f3;lica de Chile, Santiago 8330644, Chile</aff><author-notes><corresp id="c1-ijms-18-00556"><label>*</label>Correspondence: <email>akalergis@bio.puc.cl</email>; Tel.: +56-922-686-2842</corresp></author-notes><pub-date pub-type="epub"><day>04</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2017</year></pub-date><volume>18</volume><issue>3</issue><elocation-id>556</elocation-id><history><date date-type="received"><day>31</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>26</day><month>2</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 by the authors.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The human respiratory syncytial virus (hRSV) is the causative agent for high rates of hospitalizations due to viral bronchiolitis and pneumonia worldwide. Such a disease is characterized by an infection of epithelial cells of the distal airways that leads to inflammation and subsequently to respiratory failure. Upon infection, different pattern recognition receptors recognize the virus and trigger the innate immune response against the hRSV. Further, T cell immunity plays an important role for virus clearance. Based on animal studies, it is thought that the host immune response to hRSV is based on a biased T helper (Th)-2 and Th17 T cell responses with the recruitment of T cells, neutrophils and eosinophils to the lung, causing inflammation and tissue damage. In contrast, human immunity against RSV has been shown to be more complex with no definitive T cell polarization profile. Nowadays, only a humanized monoclonal antibody, known as palivizumab, is available to protect against hRSV infection in high-risk infants. However, such treatment involves several injections at a significantly high cost. For these reasons, intense research has been focused on finding novel vaccines or therapies to prevent hRSV infection in the population. Here, we comprehensively review the recent literature relative to the immunological features during hRSV infection, as well as the new insights into preventing the disease caused by this virus.</p></abstract><kwd-group><kwd>human respiratory syncytial virus</kwd><kwd>pneumonia</kwd><kwd>host immunity</kwd><kwd>vaccines and therapies</kwd></kwd-group></article-meta></front><body><sec id="sec1-ijms-18-00556"><title>1. Introduction</title><p>Pneumonia is defined as pathological inflammation of the lungs. According to the World Health Organization (WHO), pneumonia caused 920,136 child deaths in 2015, thereby making it a major public health burden worldwide [<xref rid="B1-ijms-18-00556" ref-type="bibr">1</xref>]. Further, not only children are affected by pneumonia but also the elderly, with 53,000 deaths reported annually in the &#x0003e;65 years old population in the United States alone [<xref rid="B2-ijms-18-00556" ref-type="bibr">2</xref>]. Clinical studies of childhood pneumonia contributed to the definition of pneumonia as a respiratory rate higher than 50/min, fever and chest in-drawing [<xref rid="B3-ijms-18-00556" ref-type="bibr">3</xref>]. Symptoms of pneumonia may include chest pain, wheezing and breathing difficulties [<xref rid="B4-ijms-18-00556" ref-type="bibr">4</xref>]. Pneumonia is primarily due to infectious agents, such as viruses, bacteria and fungi. <italic>Streptococcus pneumoniae</italic> and <italic>Klebsiella pneumoniae</italic> are the most common bacterial etiology, whereas the human respiratory syncytial virus (hRSV), influenza and rhinovirus are the more frequent viral causal agents of pneumonia [<xref rid="B5-ijms-18-00556" ref-type="bibr">5</xref>,<xref rid="B6-ijms-18-00556" ref-type="bibr">6</xref>]. Furthermore, virus and bacteria co-infections are usually observed in about 40% of patients with community-acquired pneumonia [<xref rid="B7-ijms-18-00556" ref-type="bibr">7</xref>].</p><p>hRSV is one of the predominant causal viruses of pneumonia [<xref rid="B8-ijms-18-00556" ref-type="bibr">8</xref>] and is also the main agent causing acute lower respiratory tract infections (ALRTIs), affecting children younger than five years old and the elderly [<xref rid="B9-ijms-18-00556" ref-type="bibr">9</xref>]. Mild manifestations of hRSV include rhinorrhea, cough, congestion, low-grade fever, reduced appetite and respiratory distress [<xref rid="B10-ijms-18-00556" ref-type="bibr">10</xref>]. However, hRSV can also cause severe symptoms, such as alveolitis, bronchiolitis and pneumonia [<xref rid="B10-ijms-18-00556" ref-type="bibr">10</xref>]. Moreover, recently, extra pulmonary manifestations, such as encephalitis, cardiopathy and hepatitis have been reported [<xref rid="B11-ijms-18-00556" ref-type="bibr">11</xref>,<xref rid="B12-ijms-18-00556" ref-type="bibr">12</xref>,<xref rid="B13-ijms-18-00556" ref-type="bibr">13</xref>,<xref rid="B14-ijms-18-00556" ref-type="bibr">14</xref>]. Importantly, global mortality due to hRSV-associated ALRTI in children younger of 5 years is estimated to be from 66,000 to 199,000 deaths per year [<xref rid="B15-ijms-18-00556" ref-type="bibr">15</xref>]. The cost in medical health expenses on hospitalizations due to hRSV infections has been estimated to be 394 million USD per year [<xref rid="B16-ijms-18-00556" ref-type="bibr">16</xref>]. To note, risk factors associated to severe cases of hRSV include elderly, age under 2 or 3 months, premature birth, chronic lung disease, congenital heart disease, simultaneous infections [<xref rid="B17-ijms-18-00556" ref-type="bibr">17</xref>,<xref rid="B18-ijms-18-00556" ref-type="bibr">18</xref>] and immunosuppression [<xref rid="B19-ijms-18-00556" ref-type="bibr">19</xref>,<xref rid="B20-ijms-18-00556" ref-type="bibr">20</xref>]. Around 36% of individuals can be reinfected at least once during the winter season [<xref rid="B21-ijms-18-00556" ref-type="bibr">21</xref>]. Along these lines, such reinfections could be caused by deficient humoral and cellular immunity response after the first virus encounter [<xref rid="B21-ijms-18-00556" ref-type="bibr">21</xref>,<xref rid="B22-ijms-18-00556" ref-type="bibr">22</xref>].</p><p>hRSV is an enveloped, negative sense, single stranded RNA virus belonging to the recently defined Pneumoviridae family, Orthopneumovirus genus. The viral genome is non-segmented RNA, 15.2 kb in length, which encodes eleven proteins and the following ten genes: <italic>NS1-NS2-N-P-M-SH-F-G-M2-L</italic> (from 3&#x02032; to 5&#x02032;) [<xref rid="B23-ijms-18-00556" ref-type="bibr">23</xref>,<xref rid="B24-ijms-18-00556" ref-type="bibr">24</xref>]. The Fusion (F), Glycoprotein (G) and Small Hydrophobic (SH) proteins are expressed at the surface whereas the Nucleoprotein (N), Phosphoprotein (P), large polymerase protein (L), Matrix protein (M) and M2-1 proteins are below the virus envelope [<xref rid="B25-ijms-18-00556" ref-type="bibr">25</xref>,<xref rid="B26-ijms-18-00556" ref-type="bibr">26</xref>]. The F protein is in charge of the fusion of the viral envelope with the host membrane [<xref rid="B27-ijms-18-00556" ref-type="bibr">27</xref>,<xref rid="B28-ijms-18-00556" ref-type="bibr">28</xref>,<xref rid="B29-ijms-18-00556" ref-type="bibr">29</xref>,<xref rid="B30-ijms-18-00556" ref-type="bibr">30</xref>]. On the other hand, the G protein has been shown to mediate the attachment of hRSV to the cell membrane [<xref rid="B31-ijms-18-00556" ref-type="bibr">31</xref>] and the fusion of the F protein with the host cell membrane [<xref rid="B32-ijms-18-00556" ref-type="bibr">32</xref>]. In contrast, the SH protein has been defined as a viroporin, thereafter allowing the entrance of low molecular weight molecules and modifying the cell permeability [<xref rid="B26-ijms-18-00556" ref-type="bibr">26</xref>,<xref rid="B33-ijms-18-00556" ref-type="bibr">33</xref>]. The L, P, M2-1 and N hRSV proteins constitute the ribonucleoprotein (RNP), which encapsides the viral RNA [<xref rid="B34-ijms-18-00556" ref-type="bibr">34</xref>,<xref rid="B35-ijms-18-00556" ref-type="bibr">35</xref>]. From this complex, the L protein regulates the replication and transcription of the hRSV RNA and the N protein is thought to protect viral RNA from nucleases [<xref rid="B23-ijms-18-00556" ref-type="bibr">23</xref>,<xref rid="B36-ijms-18-00556" ref-type="bibr">36</xref>]. The P protein is essential for the RNP complex and its phosphorylation may be required for the virus replication in vitro and in vivo [<xref rid="B34-ijms-18-00556" ref-type="bibr">34</xref>]. M2-1 protein, which also is part of the RNP complex, promotes the transcription of all hRSV genes [<xref rid="B37-ijms-18-00556" ref-type="bibr">37</xref>]. Likewise, M2-2 protein mediates the &#x0201c;switch&#x0201d; from transcription to RNA replication [<xref rid="B38-ijms-18-00556" ref-type="bibr">38</xref>]. Besides from structural proteins, the hRSV genome also includes two non-structural proteins called NS1 and NS2. Finally, as another hRSV protein, the matrix protein M that promotes viral assembly is required for hRSV replication.</p><p>Animal studies have shown that hRSV infection is characterized by the recruitment of infiltrating immune cells to the lungs, thereby producing lung damage and pulmonary inflammatory hyper reactivity. Such pulmonary inflammation is due to a Th-2 biased immune response, constituted of high levels of IL-4 and IL-13 cytokines. On the contrary, T helper (Th)-1 response, producing cytokines such as Interferon (IFN)-&#x003b3; and IL-2, has been associated with disease control and virus clearance. While such cytokine patterns have been shown in animal models, infant patients from 3 weeks to 24 months of age with acute phase hRSV bronchiolitis showed a decrease of IFN-&#x003b3;+ and an increase of IL-4+ CD4<sup>+</sup> and CD8<sup>+</sup> T cells [<xref rid="B39-ijms-18-00556" ref-type="bibr">39</xref>]. Further, patients with hRSV bronchiolitis showed a decrease in the proportion of &#x003b3;&#x003b4; T cells producing IFN-&#x003b3; in response to mitogen stimulation [<xref rid="B40-ijms-18-00556" ref-type="bibr">40</xref>].</p><p>Here, we discuss the host immune response associated to hRSV infection focusing on hRSV-associated pneumonia, the evasion of the immune response by the virus, as well as the prophylaxis and vaccines under development to prevent the disease caused by this pathogen.</p></sec><sec id="sec2-ijms-18-00556"><title>2. Host Immune Response Associated to hRSV-Pneumonia</title><p>hRSV is the major infectious agent for bronchiolitis, which is characterized by infection and inflammation of the distal bronchiolar airways. In addition, hRSV is also a causal agent of severe pneumonia. hRSV-caused pneumonia is characterized by the infection of alveolar lung regions, thereby triggering an alveolar inflammation that can eventually result in severe pulmonary disease with hypoxia and respiratory failure [<xref rid="B41-ijms-18-00556" ref-type="bibr">41</xref>]. At the lungs, airway epithelial cells (AECs), macrophages and dendritic cells (DCs) represent the first cells encountering hRSV. Upon infection, different pattern recognition receptors (PRRs) in these cells trigger a downstream innate immune cascade, including Toll-like receptors (TLRs), retinoic acid-inducible gene I (RIG-I)-like receptor (RLR) family members and NOD-like receptors (NLR) [<xref rid="B42-ijms-18-00556" ref-type="bibr">42</xref>] (<xref ref-type="fig" rid="ijms-18-00556-f001">Figure 1</xref>). At this point, different proteins of the hRSV have been found to interact with the host to modulate the innate immune response. The F protein has been shown to interact with several host proteins, such as Toll-like receptor (TLR) 4, intercellular adhesion molecule 1 (ICAM-1) and nucleolin [<xref rid="B43-ijms-18-00556" ref-type="bibr">43</xref>,<xref rid="B44-ijms-18-00556" ref-type="bibr">44</xref>]. Moreover, the SH protein has also been found to activate the NOD-like receptor family, pyrin domain containing 3 (NLRP3), thereby triggering the activation of the inflammasome [<xref rid="B45-ijms-18-00556" ref-type="bibr">45</xref>]. On the other hand, the N protein was shown to colocalize and interact with RIG-I-like receptors, the mitochondrial antiviral signalling (MAVS) protein and the melanoma differentiation-associated gene 5 (MDA5), thereby modulating the downstream innate immune response [<xref rid="B46-ijms-18-00556" ref-type="bibr">46</xref>] (<xref ref-type="fig" rid="ijms-18-00556-f001">Figure 1</xref>). Indeed, such study also demonstrated an interaction between MDA5 and N protein within inclusion bodies, suggesting that hRSV may be &#x0201c;sequestering&#x0201d; these important proteins required to trigger the triggering innate immune response [<xref rid="B46-ijms-18-00556" ref-type="bibr">46</xref>]. As a result of MDA5 sequestration, a decrease of type I IFN production is observed, which hampers the control of hRSV infection. The NLRP3 receptor, a member of the NLR family, together with proteins, such as caspase-1 and the Pyrin domain containing NLRs known as NALP proteins, constitute the inflammasome responsible for the production of IL-1&#x003b2; and IL-18 [<xref rid="B47-ijms-18-00556" ref-type="bibr">47</xref>,<xref rid="B48-ijms-18-00556" ref-type="bibr">48</xref>]. Thus, it has been shown that hRSV triggers NLRP3 inflammasome by the SH protein [<xref rid="B45-ijms-18-00556" ref-type="bibr">45</xref>] (<xref ref-type="fig" rid="ijms-18-00556-f001">Figure 1</xref>).</p><p>Such an hRSV infection promotes the recruitment of immune cells to the site of the challenge. Further, hRSV infection generates the virus-associated immunopathology characterized by up-regulation of proinflammatory cytokines including thymic stromal lymphopoetin (TSLP), Interleukin (IL)-4, IL-6, IL-10 and IL-13 and infiltration of mononuclear cells (mainly T cells), neutrophils and eosinophils (<xref ref-type="fig" rid="ijms-18-00556-f002">Figure 2</xref>) [<xref rid="B49-ijms-18-00556" ref-type="bibr">49</xref>,<xref rid="B50-ijms-18-00556" ref-type="bibr">50</xref>,<xref rid="B51-ijms-18-00556" ref-type="bibr">51</xref>,<xref rid="B52-ijms-18-00556" ref-type="bibr">52</xref>]. These cytokines fail to achieve hRSV clearance, herein favoring the persistence of the virus. To note, the TSLP together with the epithelial cell-derived IL-7, an IL-7-like cytokine, IL-25 and IL-33 are characteristic of acute asthma exacerbations and Th-2 polarized response during virus infections [<xref rid="B53-ijms-18-00556" ref-type="bibr">53</xref>]. Likewise, increased expression of TSLP has been found in asthmatic children after hRSV infection [<xref rid="B54-ijms-18-00556" ref-type="bibr">54</xref>]. Consistent with this notion, studies in animal models suggest that hRSV infection could predispose to asthma, however additional research would be needed to clearly understand such an association [<xref rid="B55-ijms-18-00556" ref-type="bibr">55</xref>]. Further, TSLP has been shown in mice to induce functional maturation of myeloid DCs (mDCs) [<xref rid="B50-ijms-18-00556" ref-type="bibr">50</xref>] and an increased expression of molecules that polarize to a Th-2 response. It is also thought that hRSV can directly impair the function of chemokines and cytokines because the G protein colocalizes with host proteins, such as CX3CR1 in ciliated lung cells [<xref rid="B56-ijms-18-00556" ref-type="bibr">56</xref>]. Such pathogenic inflammation leads to an unbalanced Th-2 and Th-17 response with low production of interferon (IFN)-&#x003b3;, which contributes to lung damage and ameliorates virus clearance [<xref rid="B57-ijms-18-00556" ref-type="bibr">57</xref>,<xref rid="B58-ijms-18-00556" ref-type="bibr">58</xref>]. Most of these data are derived from animal models, however low production of IFN-&#x003b3; has also been observed in patients suffering from hRSV bronchiolitis [<xref rid="B39-ijms-18-00556" ref-type="bibr">39</xref>,<xref rid="B40-ijms-18-00556" ref-type="bibr">40</xref>]. Importantly, the IL-17A produced at the airways after hRSV infection has been linked to neutrophil infiltration to the lungs [<xref rid="B59-ijms-18-00556" ref-type="bibr">59</xref>]. Likewise, high levels of IL-17 have been related with hRSV bronchiolitis [<xref rid="B60-ijms-18-00556" ref-type="bibr">60</xref>] and with community-acquired pneumonia [<xref rid="B61-ijms-18-00556" ref-type="bibr">61</xref>].</p><p>Furthermore, hRSV infection causes an inhibition of IFN &#x003b1;/&#x003b2; production by plasmacytoid DCs [<xref rid="B51-ijms-18-00556" ref-type="bibr">51</xref>], which is thought to be due to the ability of both NS1 and NS2 proteins to impair the activation of the type I IFN response cascade. NS1 protein inhibits the phosphorylation of Interferon Regulatory Factor 3 (IRF-3), thereby inhibiting the activation of the IFN gene promotor and blocking the JAK/STAT signaling pathway. On the other hand, the NS2 protein interacts with RIG-I preventing the activation of IRF-3 [<xref rid="B62-ijms-18-00556" ref-type="bibr">62</xref>,<xref rid="B63-ijms-18-00556" ref-type="bibr">63</xref>] (<xref ref-type="fig" rid="ijms-18-00556-f001">Figure 1</xref>). Likewise, DCs infected with NS1- and NS2-deficient hRSV displayed higher expression of cell surface DC maturation markers, such as CD80, CD83, CD86 and CD38, as compared with DCs challenged with wild type hRSV. Herein, it is thought that NS1 and NS2 inhibit DC maturation by interfering with the activation of the type I IFN response. This notion is supported by the observation that DC maturation induced by NS1- and NS2-deficient hRSV is suppressed by IFN neutralization [<xref rid="B64-ijms-18-00556" ref-type="bibr">64</xref>]. Consistently, hRSV induces only low to moderate maturation in human DCs, which is observed both in infected DCs as well in neighboring cells [<xref rid="B65-ijms-18-00556" ref-type="bibr">65</xref>]. Further, although hRSV can promote maturation in mouse DCs, these cells are rendered incapable of activating naive T cells [<xref rid="B66-ijms-18-00556" ref-type="bibr">66</xref>,<xref rid="B67-ijms-18-00556" ref-type="bibr">67</xref>], which is consistent with an inefficient T cell response against hRSV infection [<xref rid="B68-ijms-18-00556" ref-type="bibr">68</xref>]. It has been suggested that inefficient T cell activation by hRSV-infected DCs results from an impaired assembly of the immunological synapse between DCs and T cells [<xref rid="B69-ijms-18-00556" ref-type="bibr">69</xref>]. Interestingly, the N protein of hRSV has been shown to be involved in the inhibition of immunological synapse assembly (<xref ref-type="fig" rid="ijms-18-00556-f002">Figure 2</xref>) [<xref rid="B70-ijms-18-00556" ref-type="bibr">70</xref>]. Therefore, both inhibition of DC maturation and an inefficient T cell response during hRSV infection could explain the reduced IFN-&#x003b3; production observed in bronchiolitis patients.</p><p>Both CD4<sup>+</sup> and CD8<sup>+</sup> T cells have been shown to be crucial for the establishment of an efficient anti-hRSV immunity [<xref rid="B71-ijms-18-00556" ref-type="bibr">71</xref>]. Interestingly, these immune cells play a pivotal role during hRSV infection and can be either beneficial or detrimental for the host. Along these lines, human cytotoxic CD8<sup>+</sup> T cells (CTLs) have been shown to recognize peptides derived from N, SH, F, M and NS1 proteins bound to MHC class I molecules and thereby contribute to the clearance of the virus [<xref rid="B72-ijms-18-00556" ref-type="bibr">72</xref>,<xref rid="B73-ijms-18-00556" ref-type="bibr">73</xref>]. However, it has also been suggested that depletion of CD8<sup>+</sup> T cells can reduce the hRSV-associated severity in mice [<xref rid="B74-ijms-18-00556" ref-type="bibr">74</xref>]. In addition to effector CD4<sup>+</sup> and CD8<sup>+</sup> T cells, regulatory T (Treg) can contribute to modulating hRSV infection. This notion is supported by the observation that depletion of CD4<sup>+</sup>FOXP3<sup>+</sup>CD25<sup>+</sup> cells leads to an exacerbated inflammation pathology with higher weight loss and neutrophil infiltration into the lungs upon hRSV infection [<xref rid="B75-ijms-18-00556" ref-type="bibr">75</xref>,<xref rid="B76-ijms-18-00556" ref-type="bibr">76</xref>].</p></sec><sec id="sec3-ijms-18-00556"><title>3. Prophylaxis against hRSV Infection</title><p>Children hospitalized because of severe cases of hRSV-associated pneumonia are a major public health burden worldwide. Prophylaxis against hRSV infection is intended to prevent hRSV infection-derived illness during virus outbreaks or after a potential exposure to the virus.</p><sec id="sec3dot1-ijms-18-00556"><title>3.1. Antibody-Mediated Prophylaxis/Passive Immunization</title><sec id="sec3dot1dot1-ijms-18-00556"><title>3.1.1. Current Monoclonal Antibody against hRSV</title><p>Currently, palivizumab (Synagys<sup>&#x000ae;</sup>, Medimmune, Inc., Gaithersburg, MD, USA), an IgG<sub>1</sub> humanized monoclonal antibody, is the only licensed therapy to prevent severe lung disease caused by hRSV in high-risk infants. High-risk factors for hRSV disease include prematurity, bronchopulmonary dysplasia, congenital health disease, cancer, cystic fibrosis, down syndrome, neuromuscular syndrome and immune deficiency syndromes [<xref rid="B77-ijms-18-00556" ref-type="bibr">77</xref>]. Palivizumab neutralizes an epitope of the hRSV F protein and has been demonstrated to inhibit the cell-to-cell fusion and the transcription of the virus [<xref rid="B78-ijms-18-00556" ref-type="bibr">78</xref>]. Up to a 55% reduction in hospitalizations for high-risk infants during hRSV outbreaks can be obtained by the use of palivizumab [<xref rid="B79-ijms-18-00556" ref-type="bibr">79</xref>,<xref rid="B80-ijms-18-00556" ref-type="bibr">80</xref>]. Despite proven effectiveness, palivizumab requires intramuscular monthly injections throughout the hRSV outbreak, which is costly and unaffordable for most public health systems (near US$ 780 for the 50 mg vial and US$ 1416 for 100 mg, with a 15 mg/kg recommended dosage). In addition to the high cost, adverse events including hypersensitivity reactions have been reported in infants treated with palivizumab [<xref rid="B81-ijms-18-00556" ref-type="bibr">81</xref>].</p></sec><sec id="sec3dot1dot2-ijms-18-00556"><title>3.1.2. Other Monoclonal Antibodies against hRSV</title><p>To improve safety and cost/efficacy, different approaches have been explored to improve the efficiency and specificity of the passive prophylaxis against hRSV (<xref ref-type="table" rid="ijms-18-00556-t001">Table 1</xref>). One promising result was motavizumab, also known as MEDI-524, a monoclonal antibody derived from palivizumab by modifying the complementary determining regions. This monoclonal antibody showed increased affinity to the F protein as compared to palivizumab [<xref rid="B82-ijms-18-00556" ref-type="bibr">82</xref>]. Motavizumab displayed a higher neutralizing activity and an improved capacity to prevent hRSV pathology compared to palivizumab in animal models [<xref rid="B83-ijms-18-00556" ref-type="bibr">83</xref>]. Moreover, clinical trials to evaluate safety and pharmacokinetics of motavizumab obtained results equivalent to palivizumab [<xref rid="B84-ijms-18-00556" ref-type="bibr">84</xref>,<xref rid="B85-ijms-18-00556" ref-type="bibr">85</xref>,<xref rid="B86-ijms-18-00556" ref-type="bibr">86</xref>]. However, no significant reduction of viral loads nor severity of hRSV-caused illness were found in infected infants treated with motavizumab, as compared with placebo controls [<xref rid="B87-ijms-18-00556" ref-type="bibr">87</xref>]. It is important to mention that skin rashes, as an adverse event in motavizumab treated patients, were observed in all studies [<xref rid="B84-ijms-18-00556" ref-type="bibr">84</xref>,<xref rid="B85-ijms-18-00556" ref-type="bibr">85</xref>,<xref rid="B88-ijms-18-00556" ref-type="bibr">88</xref>]. In 2010, the Food and Drug Administration (FDA) declined to license motavizumab to treat high-risk hRSV infants, in part because this monoclonal antibody offered the same efficacy as palivizumab. Due to these previous results with monoclonal antibodies, currently, molecular strategies are focused on improving the neutralizing capacity but also on reducing the observed adverse effects. Promising results with derivatives of motavizumab have been reported [<xref rid="B89-ijms-18-00556" ref-type="bibr">89</xref>,<xref rid="B90-ijms-18-00556" ref-type="bibr">90</xref>]. These monoclonal antibodies contain a modified Fc region, are well tolerated and show up to 100 days of half-life in human subjects [<xref rid="B89-ijms-18-00556" ref-type="bibr">89</xref>]. Such an extended half-life together with higher levels of hRSV neutralizing antibodies as compared to palivizumab has also been reported with an anti-hRSV prefusion F monoclonal antibody, known as Medi8897 [<xref rid="B90-ijms-18-00556" ref-type="bibr">90</xref>]. A phase II clinical trial in healthy preterm infants is currently in progress [<xref rid="B91-ijms-18-00556" ref-type="bibr">91</xref>]. Due to the fact that both F and G are on the virus surface, the G protein has also been explored as an antigen to target hRSV. Indeed, anti-hRSV G monoclonal antibodies were also able to reduce pulmonary inflammation associated with hRSV in BALB/c mice [<xref rid="B92-ijms-18-00556" ref-type="bibr">92</xref>,<xref rid="B93-ijms-18-00556" ref-type="bibr">93</xref>]. However, to date, no clinical results have been reported for antibodies that target this protein as an hRSV antigen.</p></sec><sec id="sec3dot1dot3-ijms-18-00556"><title>3.1.3. Maternal Immunization against hRSV</title><p>Another strategy for vaccine research against hRSV has been maternal immunization. It was previously demonstrated that RSV-neutralizing antibodies are transferred efficiently through the placenta from pregnant women to newborns [<xref rid="B94-ijms-18-00556" ref-type="bibr">94</xref>]. Consistently, studies in cotton rats showed that pups gestated by hRSV-primed mothers were protected from viral replication in the lungs [<xref rid="B95-ijms-18-00556" ref-type="bibr">95</xref>]. Further, maternal immune protection was also observed in lambs after immunization with a subunit vaccine based on the F protein of hRSV with an adjuvant (&#x00394;F/TriAdj). Promisingly, those newborns that received maternal antibodies showed less virus production and lung pathology as compared with control animals [<xref rid="B96-ijms-18-00556" ref-type="bibr">96</xref>]. Immunization with a vaccine has already been found to be safe and immunogenic in healthy women of childbearing age in a phase II clinical trial [<xref rid="B97-ijms-18-00556" ref-type="bibr">97</xref>]. This recombinant F nanoparticle formulation is currently on phase III clinical trial on women of childbearing age during their third-trimester of pregnancy and a phase III clinical trial in older adults with this formulation has been recently completed [<xref rid="B98-ijms-18-00556" ref-type="bibr">98</xref>,<xref rid="B99-ijms-18-00556" ref-type="bibr">99</xref>].</p></sec></sec><sec id="sec3dot2-ijms-18-00556"><title>3.2. Active Immunization</title><p>The first approach to prevent hRSV was the formaldehyde-inactivated hRSV vaccine, which caused an exacerbated respiratory disease characterized by excessive inflammation with a Th-2 biased response [<xref rid="B100-ijms-18-00556" ref-type="bibr">100</xref>]. Indeed, up to 80% of hospitalizations in children receiving this vaccine were reported [<xref rid="B101-ijms-18-00556" ref-type="bibr">101</xref>,<xref rid="B102-ijms-18-00556" ref-type="bibr">102</xref>]. Therefore, after that negative experience, therapies and vaccines approaches against the hRSV have been focused on achieving high immunogenicity but without promoting the exacerbated respiratory disease. Approximately sixty hRSV vaccine candidates are undergoing preclinical or clinical development at the moment [<xref rid="B103-ijms-18-00556" ref-type="bibr">103</xref>]. A summary of the vaccines currently under research to prevent the hRSV infections is shown in <xref ref-type="table" rid="ijms-18-00556-t001">Table 1</xref>.</p><sec id="sec3dot2dot1-ijms-18-00556"><title>3.2.1. Live Attenuated Vaccines</title><p>The strategy of live attenuated vaccines was explored early to prevent hRSV disease. Current live attenuated vaccines have been engineered by reverse genetics. For instance, the deletion of M2-2 protein was used to obtain three candidates of attenuated vaccines [<xref rid="B133-ijms-18-00556" ref-type="bibr">133</xref>]. One of them, known as hRSV LID &#x00394;M2-2, has already shown stability, hRSV attenuation and anti-F serum IgG antibody responses in phase I clinical trials [<xref rid="B109-ijms-18-00556" ref-type="bibr">109</xref>]. The other two candidates with the deletion of the M2-2 protein are currently under evaluation in phase I clinical trials [<xref rid="B103-ijms-18-00556" ref-type="bibr">103</xref>]. Further, attenuating NS2 gene deletion has been explored as a strategy to develop a live attenuated RSV vaccine [<xref rid="B110-ijms-18-00556" ref-type="bibr">110</xref>], which is currently in phase I clinical evaluation. Likewise, codon-reoptimization of NS1, NS2 and G, together with the deletion of SH proteins led to the generation of a stable attenuated hRSV vaccine, known as OE4 [<xref rid="B134-ijms-18-00556" ref-type="bibr">134</xref>], which showed protection and lack of disease enhancement in mice and cotton rats [<xref rid="B134-ijms-18-00556" ref-type="bibr">134</xref>].</p></sec><sec id="sec3dot2dot2-ijms-18-00556"><title>3.2.2. Recombinant Vector Vaccines against hRSV</title><p>In addition to live attenuated vaccines, recombinant vectored vaccines have also been explored for generating hRSV vaccines. For instance, Parainfluenza virus type 3 (PIV3) has been used as a vector to express hRSV proteins of interest [<xref rid="B135-ijms-18-00556" ref-type="bibr">135</xref>,<xref rid="B136-ijms-18-00556" ref-type="bibr">136</xref>]. Thus, recombinant bovine/human PIV3 (rB/HPIV3) expressing the G and F proteins can induce high anti-hRSV serum titers as well as protection against the virus in hamsters [<xref rid="B136-ijms-18-00556" ref-type="bibr">136</xref>,<xref rid="B137-ijms-18-00556" ref-type="bibr">137</xref>]. Recently, a partially stabilized prefusion form of the F protein was included in the genome of rB/HPIV3 to achieve higher quality of anti-hRSV-neutralizing antibodies in hamsters and rhesus monkeys than the previous formulation [<xref rid="B106-ijms-18-00556" ref-type="bibr">106</xref>]. Also, the PIV type 5 (PIV5) has been shown to be an effective vector to express F and G proteins of hRSV, herein offering protection against the virus in mice [<xref rid="B132-ijms-18-00556" ref-type="bibr">132</xref>].</p><p>Another successful recombinant approach to generate recombinant vaccines against hRSV was the Bacille Calmette-Gu&#x000e9;rin (BCG), which can efficiently express hRSV proteins [<xref rid="B71-ijms-18-00556" ref-type="bibr">71</xref>,<xref rid="B107-ijms-18-00556" ref-type="bibr">107</xref>]. BCG is an attenuated strain of <italic>Mycobacterium bovis</italic> and by itself displays a strong immunogenic capacity that promotes the production of Th-1 type cytokines, which are required to reduce hRSV dissemination and disease. Based on these properties, BCG was engineered to express various hRSV antigens [<xref rid="B71-ijms-18-00556" ref-type="bibr">71</xref>]. Importantly, immunization with recombinant BCG strains expressing M2 or N proteins conferred protection against hRSV in mice and led to an early T cell recruitment to the lungs. Immunized animals showed no lung damage, lower viral loads and a Th1/Th2 balance after a challenge with hRSV [<xref rid="B71-ijms-18-00556" ref-type="bibr">71</xref>,<xref rid="B107-ijms-18-00556" ref-type="bibr">107</xref>]. Furthermore, a single dose of rBCG-N-hRSV manufactured under Good Manufacturing Practices (GMP) was shown to maintain those immunological properties and promoted long-lasting immunity in mice [<xref rid="B108-ijms-18-00556" ref-type="bibr">108</xref>].</p><p>Furthermore, adenovirus has also been used as a vector to express hRSV antigens. Up to seven hRSV vaccine candidates have used adenovirus as a vector [<xref rid="B103-ijms-18-00556" ref-type="bibr">103</xref>]. Adenovirus vectors expressing the hRSV F protein were immunogenic in mice and in cotton rats [<xref rid="B126-ijms-18-00556" ref-type="bibr">126</xref>,<xref rid="B127-ijms-18-00556" ref-type="bibr">127</xref>,<xref rid="B128-ijms-18-00556" ref-type="bibr">128</xref>]. Further, the vaccine known as PanAd3-RSV showed protection against hRSV in calves [<xref rid="B138-ijms-18-00556" ref-type="bibr">138</xref>] and a Phase I clinical trial has been recently completed [<xref rid="B131-ijms-18-00556" ref-type="bibr">131</xref>]. On the other hand, baculovirus expressing the F protein in combination with virus-induced signalling adaptor reduced Th-2 responses and the immunopathology associated to hRSV infection [<xref rid="B139-ijms-18-00556" ref-type="bibr">139</xref>,<xref rid="B140-ijms-18-00556" ref-type="bibr">140</xref>]. Moreover, the F protein of hRSV and the hemagglutinin-neuraminidase protein of PIV were inserted into the Sendai virus genome to generate a vaccine inducing long-lasting protection against both hRSV and PIV in cotton rats [<xref rid="B141-ijms-18-00556" ref-type="bibr">141</xref>]. Finally, a modified vaccine Ankara virus expressing hRSV proteins was shown to protect against virus infection in macaques [<xref rid="B129-ijms-18-00556" ref-type="bibr">129</xref>,<xref rid="B130-ijms-18-00556" ref-type="bibr">130</xref>] and to be safe and immunogenic in adults. Phase III clinical trials are currently ongoing for this vaccine [<xref rid="B142-ijms-18-00556" ref-type="bibr">142</xref>].</p></sec><sec id="sec3dot2dot3-ijms-18-00556"><title>3.2.3. Virus-Like Particles (VLPs) as Vaccines for hRSV</title><p>Virus-like particles (VLPs), which consist of viral proteins assembled without genetic material, have also been used as a vaccine strategy against hRSV [<xref rid="B114-ijms-18-00556" ref-type="bibr">114</xref>,<xref rid="B115-ijms-18-00556" ref-type="bibr">115</xref>]. Thus, it was shown that VLPs containing the matrix protein of the human metapneumovirus (hMPV) together with the recombinant postfusion and prefusion F hybrids of hRSV promoted high levels of neutralizing antibodies, a Th-1 mediated response and protected against lung RSV infection [<xref rid="B114-ijms-18-00556" ref-type="bibr">114</xref>]. Likewise, a combination of VLPs containing F and G proteins together with F-encoding plasmid DNA was found to be protective against hRSV disease by reducing weight loss and lung inflammatory damage [<xref rid="B143-ijms-18-00556" ref-type="bibr">143</xref>]. Moreover, the bacterium-like particle (BLP) technology has also been used to develop a mucosal vaccine by including the F protein as an antigen to protect against hRSV. Such a RSV BLP vaccine reduced virus titers and resulted in higher titers of F-specific IgG in sera from cotton rats and mice challenged with hRSV [<xref rid="B116-ijms-18-00556" ref-type="bibr">116</xref>]. Further, a Phase I clinical trial is in progress to assess the safety, reactogenicity and tolerability of two intranasal dose levels of this vaccine [<xref rid="B117-ijms-18-00556" ref-type="bibr">117</xref>]. Further, the SH protein has also been underscored recently as a new target for vaccination against hRSV. As a vaccine candidate approach, a peptide derived from the SH ectodomain (SHe) was conjugated to the keyhole limpet hemocyanin [<xref rid="B144-ijms-18-00556" ref-type="bibr">144</xref>]. This vaccine showed protection against hRSV and induced high levels of SH-specific IgGs in cotton rats and mice, however, sera from these animals showed no neutralizing capacity against hRSV [<xref rid="B144-ijms-18-00556" ref-type="bibr">144</xref>]. Further, a phase I clinical trial was conducted with an hRSV vaccine containing the SH antigen and a novel adjuvant DepoVax or SH antigen co-administered with aluminum hydroxide, showing safety in vaccinated subjects [<xref rid="B145-ijms-18-00556" ref-type="bibr">145</xref>].</p><p>Nanomedicine has appeared in the last few years to contribute to hRSV research vaccines. The reason for using such a technology is because it has been postulated that the density of the immunogens could be key for triggering the humoral immune response [<xref rid="B146-ijms-18-00556" ref-type="bibr">146</xref>]. Nanoparticles technology can assemble several antigens in sizes ranging from 2 to 200 nm, thereby creating a high density &#x0201c;cocktail antigen&#x0201d;. Specifically, a high density of viral antigens facilitates antibody secretion and the formation of memory B cells [<xref rid="B146-ijms-18-00556" ref-type="bibr">146</xref>]. Along these lines, a nanoparticle vaccine based on the F protein of hRSV was shown to be well tolerated in a Phase I clinical trial. Further, this vaccine was immunogenic in humans and led to high microneutralization antibody titers against the hRSV A Tracy and hRSV B strains. Further, this trial showed that the F hRSV nanoparticle vaccine induced an immune response against the epitope antigen site II by adding palivizumab in competitive assays [<xref rid="B147-ijms-18-00556" ref-type="bibr">147</xref>]. In addition, this vaccine formulation was also used for maternal immunization as previously described [<xref rid="B97-ijms-18-00556" ref-type="bibr">97</xref>]. Other VLPs with nanoparticles expressing hRSV glycoproteins also showed immunogenicity and the authors of the study demonstrated that alveolar macrophages are responsible for preventing detrimental infiltration by neutrophils, eosinophils and T cells, as well as mucus and inflammatory cytokine production [<xref rid="B148-ijms-18-00556" ref-type="bibr">148</xref>]. Soluble nanorings composed of N protomers containing the epitope of the hRSV F targeted by palivizumab, known as N-FsII-nanorings, are another strategy [<xref rid="B120-ijms-18-00556" ref-type="bibr">120</xref>]. Mice immunized with N-FsII-nanorings were protected from hRSV-caused disease, however, they showed no detectable neutralizing antibodies [<xref rid="B120-ijms-18-00556" ref-type="bibr">120</xref>]. Moreover, patches loaded with N-nanorings have been found to protect against hRSV in pigs and have been demonstrated to be delivered efficiently through the skin and to reach Langerhans cells [<xref rid="B121-ijms-18-00556" ref-type="bibr">121</xref>].</p></sec></sec></sec><sec id="sec4-ijms-18-00556"><title>4. Concluding Remarks</title><p>The severe cases of pneumonia associated to hRSV infection are still a major public health burden worldwide and currently there are no licensed vaccines available. The only licensed treatment to prevent hRSV infections is the Palimizumab, an anti-F hRSV protein humanized monoclonal antibody that can reduce hRSV-associated hospitalizations by up to 55%, however, at a high cost [<xref rid="B149-ijms-18-00556" ref-type="bibr">149</xref>]. Nowadays, several studies are in progress to generate a vaccine against hRSV, including live attenuated, viral-like particles and passive immunizations. Nevertheless, currently, there are few studies on human clinical trials or that have proven long-lasting immunity. Thus, new vaccines and therapies are urgently needed to reduce the high rate of hospitalizations caused by hRSV.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported by the Millennium Institute on Immunology and Immunotherapy from Chile (P09/016-F for AMK), CONICYT/FONDECYT POSTDOCTORADO No. 3160249, FONDECYT grants number: 1150862, 1070352, 1050979, 1040349, 1100926, 1110397, 1131012, 1140010, 1140011, 3140455. Biomedical Research Consortium (BMRC 13CTI-21526 for AMK). FONDEF grant D11I1080.</p></ack><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-ijms-18-00556"><label>1.</label><element-citation publication-type="webpage">
<person-group person-group-type="author"><collab>WHO</collab></person-group>
<article-title>Pneumonia</article-title>
<comment>Avaliable online: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/factsheets/fs331/en/">http://www.who.int/mediacentre/factsheets/fs331/en/</ext-link></comment>
<date-in-citation>(accessed on 28 February 2017)</date-in-citation>
</element-citation></ref><ref id="B2-ijms-18-00556"><label>2.</label><element-citation publication-type="gov">
<person-group person-group-type="author"><collab>CDC</collab></person-group>
<article-title>Pneumonia. Atlanta, GA: US Department of Health and Human Services, CDC, 2016</article-title>
<comment>Avaliable online: <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/pneumonia/index.html">http://www.cdc.gov/pneumonia/index.html</ext-link></comment>
<date-in-citation>(accessed on 28 February 2017)</date-in-citation>
</element-citation></ref><ref id="B3-ijms-18-00556"><label>3.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scott</surname><given-names>J.A.G.</given-names></name><name><surname>Wonodi</surname><given-names>C.</given-names></name><name><surname>Mo&#x000ef;si</surname><given-names>J.C.</given-names></name><name><surname>Deloria-Knoll</surname><given-names>M.</given-names></name><name><surname>DeLuca</surname><given-names>A.N.</given-names></name><name><surname>Karron</surname><given-names>R.A.</given-names></name><name><surname>Bhat</surname><given-names>N.</given-names></name><name><surname>Murdoch</surname><given-names>D.R.</given-names></name><name><surname>Crawley</surname><given-names>J.</given-names></name><name><surname>Levine</surname><given-names>O.S.</given-names></name><etal/></person-group>
<article-title>The definition of pneumonia, the assessment of severity, and clinical standardization in the pneumonia etiology research for child health study</article-title>
<source>Clin. Infect. Dis.</source>
<year>2012</year>
<volume>54</volume>
<fpage>S109</fpage>
<lpage>S116</lpage>
<pub-id pub-id-type="doi">10.1093/cid/cir1065</pub-id>
<?supplied-pmid 22403224?><pub-id pub-id-type="pmid">22403224</pub-id></element-citation></ref><ref id="B4-ijms-18-00556"><label>4.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nascimento-Carvalho</surname><given-names>A.C.</given-names></name><name><surname>Ruuskanen</surname><given-names>O.</given-names></name><name><surname>Nascimento-Carvalho</surname><given-names>C.M.</given-names></name></person-group>
<article-title>Comparison of the frequency of bacterial and viral infections among children with community-acquired pneumonia hospitalized across distinct severity categories: A prospective cross-sectional study</article-title>
<source>BMC Pediatr.</source>
<year>2016</year>
<volume>16</volume>
<elocation-id>105</elocation-id>
<pub-id pub-id-type="doi">10.1186/s12887-016-0645-3</pub-id>
<?supplied-pmid 27449898?><pub-id pub-id-type="pmid">27449898</pub-id></element-citation></ref><ref id="B5-ijms-18-00556"><label>5.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>El Seify</surname><given-names>M.Y.</given-names></name><name><surname>Fouda</surname><given-names>E.M.</given-names></name><name><surname>Ibrahim</surname><given-names>H.M.</given-names></name><name><surname>Fathy</surname><given-names>M.M.</given-names></name><name><surname>Husseiny</surname><given-names>A.A.A.</given-names></name><name><surname>Khater</surname><given-names>W.S.</given-names></name><name><surname>El Deen</surname><given-names>N.N.</given-names></name><name><surname>Abouzeid</surname><given-names>H.G.</given-names></name><name><surname>Hegazy</surname><given-names>N.R.</given-names></name><name><surname>Elbanna</surname><given-names>H.S.</given-names></name></person-group>
<article-title>Microbial etiology of community-acquired pneumonia among infants and children admitted to the pediatric hospital, Ain Shams University</article-title>
<source>Eur. J. Microbiol Immunol</source>
<year>2016</year>
<volume>6</volume>
<fpage>206</fpage>
<lpage>214</lpage>
<pub-id pub-id-type="doi">10.1556/1886.2016.00022</pub-id>
<?supplied-pmid 27766169?><pub-id pub-id-type="pmid">27766169</pub-id></element-citation></ref><ref id="B6-ijms-18-00556"><label>6.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bashir</surname><given-names>U.</given-names></name><name><surname>Nisar</surname><given-names>N.</given-names></name><name><surname>Arshad</surname><given-names>Y.</given-names></name><name><surname>Alam</surname><given-names>M.M.</given-names></name><name><surname>Ashraf</surname><given-names>A.</given-names></name><name><surname>Sadia</surname><given-names>H.</given-names></name><name><surname>Kazi</surname><given-names>B.M.</given-names></name><name><surname>Zaidi</surname><given-names>S.S.</given-names></name></person-group>
<article-title>Respiratory syncytial virus and influenza are the key viral pathogens in children &#x0003c;2 years hospitalized with bronchiolitis and pneumonia in islamabad pakistan</article-title>
<source>Arch. Virol.</source>
<year>2016</year>
<pub-id pub-id-type="doi">10.1007/s00705-016-3146-7</pub-id>
</element-citation></ref><ref id="B7-ijms-18-00556"><label>7.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Voiriot</surname><given-names>G.</given-names></name><name><surname>Visseaux</surname><given-names>B.</given-names></name><name><surname>Cohen</surname><given-names>J.</given-names></name><name><surname>Nguyen</surname><given-names>L.B.</given-names></name><name><surname>Neuville</surname><given-names>M.</given-names></name><name><surname>Morbieu</surname><given-names>C.</given-names></name><name><surname>Burdet</surname><given-names>C.</given-names></name><name><surname>Radjou</surname><given-names>A.</given-names></name><name><surname>Lescure</surname><given-names>F.X.</given-names></name><name><surname>Smonig</surname><given-names>R.</given-names></name><etal/></person-group>
<article-title>Viral-bacterial coinfection affects the presentation and alters the prognosis of severe community-acquired pneumonia</article-title>
<source>Crit. Care</source>
<year>2016</year>
<volume>20</volume>
<fpage>375</fpage>
<pub-id pub-id-type="doi">10.1186/s13054-016-1517-9</pub-id>
<?supplied-pmid 27852281?><pub-id pub-id-type="pmid">27852281</pub-id></element-citation></ref><ref id="B8-ijms-18-00556"><label>8.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jain</surname><given-names>S.</given-names></name><name><surname>Williams</surname><given-names>D.J.</given-names></name><name><surname>Arnold</surname><given-names>S.R.</given-names></name><name><surname>Ampofo</surname><given-names>K.</given-names></name><name><surname>Bramley</surname><given-names>A.M.</given-names></name><name><surname>Reed</surname><given-names>C.</given-names></name><name><surname>Stockmann</surname><given-names>C.</given-names></name><name><surname>Anderson</surname><given-names>E.J.</given-names></name><name><surname>Grijalva</surname><given-names>C.G.</given-names></name><name><surname>Self</surname><given-names>W.H.</given-names></name><etal/></person-group>
<article-title>Community-acquired pneumonia requiring hospitalization among U.S. children</article-title>
<source>N. Engl. J. Med.</source>
<year>2015</year>
<volume>372</volume>
<fpage>835</fpage>
<lpage>845</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1405870</pub-id>
<?supplied-pmid 25714161?><pub-id pub-id-type="pmid">25714161</pub-id></element-citation></ref><ref id="B9-ijms-18-00556"><label>9.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Calvo</surname><given-names>C.</given-names></name><name><surname>Garcia-Garcia</surname><given-names>M.L.</given-names></name><name><surname>Blanco</surname><given-names>C.</given-names></name><name><surname>Vazquez</surname><given-names>M.C.</given-names></name><name><surname>Frias</surname><given-names>M.E.</given-names></name><name><surname>Perez-Brena</surname><given-names>P.</given-names></name><name><surname>Casas</surname><given-names>I.</given-names></name></person-group>
<article-title>Multiple simultaneous viral infections in infants with acute respiratory tract infections in spain</article-title>
<source>J. Clin. Virol.</source>
<year>2008</year>
<volume>42</volume>
<fpage>268</fpage>
<lpage>272</lpage>
<pub-id pub-id-type="doi">10.1016/j.jcv.2008.03.012</pub-id>
<?supplied-pmid 18455958?><pub-id pub-id-type="pmid">18455958</pub-id></element-citation></ref><ref id="B10-ijms-18-00556"><label>10.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Collins</surname><given-names>P.L.</given-names></name><name><surname>Melero</surname><given-names>J.A.</given-names></name></person-group>
<article-title>Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years</article-title>
<source>Virus Res.</source>
<year>2011</year>
<volume>162</volume>
<fpage>80</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="doi">10.1016/j.virusres.2011.09.020</pub-id>
<?supplied-pmid 21963675?><pub-id pub-id-type="pmid">21963675</pub-id></element-citation></ref><ref id="B11-ijms-18-00556"><label>11.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sweetman</surname><given-names>L.L.</given-names></name><name><surname>Ng</surname><given-names>Y.T.</given-names></name><name><surname>Butler</surname><given-names>I.J.</given-names></name><name><surname>Bodensteiner</surname><given-names>J.B.</given-names></name></person-group>
<article-title>Neurologic complications associated with respiratory syncytial virus</article-title>
<source>Pediatr. Neurol.</source>
<year>2005</year>
<volume>32</volume>
<fpage>307</fpage>
<lpage>310</lpage>
<pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2005.01.010</pub-id>
<?supplied-pmid 15866430?><pub-id pub-id-type="pmid">15866430</pub-id></element-citation></ref><ref id="B12-ijms-18-00556"><label>12.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eisenhut</surname><given-names>M.</given-names></name></person-group>
<article-title>Extrapulmonary manifestations of severe respiratory syncytial virus infection&#x02014;A systematic review</article-title>
<source>Crit. Care</source>
<year>2006</year>
<volume>10</volume>
<fpage>R107</fpage>
<pub-id pub-id-type="doi">10.1186/cc4984</pub-id>
<?supplied-pmid 16859512?><pub-id pub-id-type="pmid">16859512</pub-id></element-citation></ref><ref id="B13-ijms-18-00556"><label>13.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Esposito</surname><given-names>S.</given-names></name><name><surname>Salice</surname><given-names>P.</given-names></name><name><surname>Bosis</surname><given-names>S.</given-names></name><name><surname>Ghiglia</surname><given-names>S.</given-names></name><name><surname>Tremolati</surname><given-names>E.</given-names></name><name><surname>Tagliabue</surname><given-names>C.</given-names></name><name><surname>Gualtieri</surname><given-names>L.</given-names></name><name><surname>Barbier</surname><given-names>P.</given-names></name><name><surname>Galeone</surname><given-names>C.</given-names></name><name><surname>Marchisio</surname><given-names>P.</given-names></name><etal/></person-group>
<article-title>Altered cardiac rhythm in infants with bronchiolitis and respiratory syncytial virus infection</article-title>
<source>BMC Infect. Dis.</source>
<year>2010</year>
<volume>10</volume>
<elocation-id>305</elocation-id>
<pub-id pub-id-type="doi">10.1186/1471-2334-10-305</pub-id>
<?supplied-pmid 20969802?><pub-id pub-id-type="pmid">20969802</pub-id></element-citation></ref><ref id="B14-ijms-18-00556"><label>14.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kirin</surname><given-names>B.K.</given-names></name><name><surname>Topic</surname><given-names>R.Z.</given-names></name><name><surname>Dodig</surname><given-names>S.</given-names></name></person-group>
<article-title>Hepatitis during respiratory syncytial virus infection&#x02014;A case report</article-title>
<source>Biochem. Med.</source>
<year>2013</year>
<volume>23</volume>
<fpage>112</fpage>
<lpage>116</lpage>
<pub-id pub-id-type="doi">10.11613/BM.2013.014</pub-id>
</element-citation></ref><ref id="B15-ijms-18-00556"><label>15.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nair</surname><given-names>H.</given-names></name><name><surname>Nokes</surname><given-names>D.J.</given-names></name><name><surname>Gessner</surname><given-names>B.D.</given-names></name><name><surname>Dherani</surname><given-names>M.</given-names></name><name><surname>Madhi</surname><given-names>S.A.</given-names></name><name><surname>Singleton</surname><given-names>R.J.</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>K.L.</given-names></name><name><surname>Roca</surname><given-names>A.</given-names></name><name><surname>Wright</surname><given-names>P.F.</given-names></name><name><surname>Bruce</surname><given-names>N.</given-names></name><etal/></person-group>
<article-title>Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis</article-title>
<source>Lancet</source>
<year>2010</year>
<volume>375</volume>
<fpage>1545</fpage>
<lpage>1555</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(10)60206-1</pub-id>
<pub-id pub-id-type="pmid">20399493</pub-id></element-citation></ref><ref id="B16-ijms-18-00556"><label>16.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Paramore</surname><given-names>L.C.</given-names></name><name><surname>Ciuryla</surname><given-names>V.</given-names></name><name><surname>Ciesla</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name></person-group>
<article-title>Economic impact of respiratory syncytial virus-related illness in the us: An analysis of national databases</article-title>
<source>PharmacoEconomics</source>
<year>2004</year>
<volume>22</volume>
<fpage>275</fpage>
<lpage>284</lpage>
<pub-id pub-id-type="doi">10.2165/00019053-200422050-00001</pub-id>
<?supplied-pmid 15061677?><pub-id pub-id-type="pmid">15061677</pub-id></element-citation></ref><ref id="B17-ijms-18-00556"><label>17.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prendergast</surname><given-names>A.J.</given-names></name><name><surname>Klenerman</surname><given-names>P.</given-names></name><name><surname>Goulder</surname><given-names>P.J.</given-names></name></person-group>
<article-title>The impact of differential antiviral immunity in children and adults</article-title>
<source>Nat. Rev. Immunol.</source>
<year>2012</year>
<volume>12</volume>
<fpage>636</fpage>
<lpage>648</lpage>
<pub-id pub-id-type="doi">10.1038/nri3277</pub-id>
<?supplied-pmid 22918466?><pub-id pub-id-type="pmid">22918466</pub-id></element-citation></ref><ref id="B18-ijms-18-00556"><label>18.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vanden Driessche</surname><given-names>K.</given-names></name><name><surname>Persson</surname><given-names>A.</given-names></name><name><surname>Marais</surname><given-names>B.J.</given-names></name><name><surname>Fink</surname><given-names>P.J.</given-names></name><name><surname>Urdahl</surname><given-names>K.B.</given-names></name></person-group>
<article-title>Immune vulnerability of infants to tuberculosis</article-title>
<source>Clin. Dev. Immunol.</source>
<year>2013</year>
<fpage>781320</fpage>
<pub-id pub-id-type="doi">10.1155/2013/781320</pub-id>
<?supplied-pmid 23762096?><pub-id pub-id-type="pmid">23762096</pub-id></element-citation></ref><ref id="B19-ijms-18-00556"><label>19.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miller</surname><given-names>R.F.</given-names></name><name><surname>Loveday</surname><given-names>C.</given-names></name><name><surname>Holton</surname><given-names>J.</given-names></name><name><surname>Sharvell</surname><given-names>Y.</given-names></name><name><surname>Patel</surname><given-names>G.</given-names></name><name><surname>Brink</surname><given-names>N.S.</given-names></name></person-group>
<article-title>Community-based respiratory viral infections in HIV positive patients with lower respiratory tract disease: A prospective bronchoscopic study</article-title>
<source>Genitourin Med.</source>
<year>1996</year>
<volume>72</volume>
<fpage>9</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="doi">10.1136/sti.72.1.9</pub-id>
<?supplied-pmid 8655183?><pub-id pub-id-type="pmid">8655183</pub-id></element-citation></ref><ref id="B20-ijms-18-00556"><label>20.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hawkinson</surname><given-names>D.J.</given-names></name><name><surname>Ison</surname><given-names>M.G.</given-names></name></person-group>
<article-title>Respiratory viruses: Influenza, RSV, and adenovirus in kidney transplantation</article-title>
<source>Semin. Nephrol.</source>
<year>2016</year>
<volume>36</volume>
<fpage>417</fpage>
<lpage>427</lpage>
<pub-id pub-id-type="doi">10.1016/j.semnephrol.2016.05.018</pub-id>
<?supplied-pmid 27772626?><pub-id pub-id-type="pmid">27772626</pub-id></element-citation></ref><ref id="B21-ijms-18-00556"><label>21.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hall</surname><given-names>C.B.</given-names></name><name><surname>Walsh</surname><given-names>E.E.</given-names></name><name><surname>Long</surname><given-names>C.E.</given-names></name><name><surname>Schnabel</surname><given-names>K.C.</given-names></name></person-group>
<article-title>Immunity to and frequency of reinfection with respiratory syncytial virus</article-title>
<source>J. Infect. Dis.</source>
<year>1991</year>
<volume>163</volume>
<fpage>4</fpage>
<pub-id pub-id-type="doi">10.1093/infdis/163.4.693</pub-id>
</element-citation></ref><ref id="B22-ijms-18-00556"><label>22.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bont</surname><given-names>L.</given-names></name><name><surname>Versteegh</surname><given-names>J.</given-names></name><name><surname>Swelsen</surname><given-names>W.T.</given-names></name><name><surname>Heijnen</surname><given-names>C.J.</given-names></name><name><surname>Kavelaars</surname><given-names>A.</given-names></name><name><surname>Brus</surname><given-names>F.</given-names></name><name><surname>Draaisma</surname><given-names>J.M.</given-names></name><name><surname>Pekelharing-Berghuis</surname><given-names>M.</given-names></name><name><surname>van Diemen-Steenvoorde</surname><given-names>R.A.</given-names></name><name><surname>Kimpen</surname><given-names>J.L.</given-names></name></person-group>
<article-title>Natural reinfection with respiratory syncytial virus does not boost virus-specific T cell immunity</article-title>
<source>Pediatr. Res.</source>
<year>2002</year>
<volume>52</volume>
<fpage>363</fpage>
<lpage>367</lpage>
<pub-id pub-id-type="doi">10.1203/00006450-200209000-00009</pub-id>
<?supplied-pmid 12193668?><pub-id pub-id-type="pmid">12193668</pub-id></element-citation></ref><ref id="B23-ijms-18-00556"><label>23.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hacking</surname><given-names>D.</given-names></name><name><surname>Hull</surname><given-names>J.</given-names></name></person-group>
<article-title>Respiratory syncytial virus&#x02014;Viral biology and the host response</article-title>
<source>J. Infect.</source>
<year>2002</year>
<volume>45</volume>
<fpage>18</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="doi">10.1053/jinf.2002.1015</pub-id>
<?supplied-pmid 12217726?><pub-id pub-id-type="pmid">12217726</pub-id></element-citation></ref><ref id="B24-ijms-18-00556"><label>24.</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Collins</surname><given-names>P.</given-names></name><name><surname>Chanock</surname><given-names>R.</given-names></name><name><surname>Murphy</surname><given-names>B.</given-names></name></person-group>
<source>Respiratory Syncytial Virus</source>
<publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name>
<publisher-loc>Philadelphia, PA, USA</publisher-loc>
<year>2001</year>
</element-citation></ref><ref id="B25-ijms-18-00556"><label>25.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Collins</surname><given-names>P.L.</given-names></name><name><surname>Fearns</surname><given-names>R.</given-names></name><name><surname>Graham</surname><given-names>B.S.</given-names></name></person-group>
<article-title>Respiratory syncytial virus: Virology, reverse genetics, and pathogenesis of disease</article-title>
<source>Curr. Top. Microbiol. Immunol.</source>
<year>2013</year>
<volume>372</volume>
<fpage>3</fpage>
<lpage>38</lpage>
<?supplied-pmid 24362682?><pub-id pub-id-type="pmid">24362682</pub-id></element-citation></ref><ref id="B26-ijms-18-00556"><label>26.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fuentes</surname><given-names>S.</given-names></name><name><surname>Tran</surname><given-names>K.C.</given-names></name><name><surname>Luthra</surname><given-names>P.</given-names></name><name><surname>Teng</surname><given-names>M.N.</given-names></name><name><surname>He</surname><given-names>B.</given-names></name></person-group>
<article-title>Function of the respiratory syncytial virus small hydrophobic protein</article-title>
<source>J. Virol.</source>
<year>2007</year>
<volume>81</volume>
<fpage>8361</fpage>
<lpage>8366</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.02717-06</pub-id>
<?supplied-pmid 17494063?><pub-id pub-id-type="pmid">17494063</pub-id></element-citation></ref><ref id="B27-ijms-18-00556"><label>27.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mastrangelo</surname><given-names>P.</given-names></name><name><surname>Hegele</surname><given-names>R.G.</given-names></name></person-group>
<article-title>RSV fusion: Time for a new model</article-title>
<source>Viruses</source>
<year>2013</year>
<volume>5</volume>
<fpage>873</fpage>
<lpage>885</lpage>
<pub-id pub-id-type="doi">10.3390/v5030873</pub-id>
<?supplied-pmid 23518574?><pub-id pub-id-type="pmid">23518574</pub-id></element-citation></ref><ref id="B28-ijms-18-00556"><label>28.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McLellan</surname><given-names>J.S.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Joyce</surname><given-names>M.G.</given-names></name><name><surname>Sastry</surname><given-names>M.</given-names></name><name><surname>Stewart-Jones</surname><given-names>G.B.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Srivatsan</surname><given-names>S.</given-names></name><name><surname>Zheng</surname><given-names>A.</given-names></name><etal/></person-group>
<article-title>Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus</article-title>
<source>Science</source>
<year>2013</year>
<volume>342</volume>
<fpage>592</fpage>
<lpage>598</lpage>
<pub-id pub-id-type="doi">10.1126/science.1243283</pub-id>
<?supplied-pmid 24179220?><pub-id pub-id-type="pmid">24179220</pub-id></element-citation></ref><ref id="B29-ijms-18-00556"><label>29.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Behera</surname><given-names>A.K.</given-names></name><name><surname>Matsuse</surname><given-names>H.</given-names></name><name><surname>Kumar</surname><given-names>M.</given-names></name><name><surname>Kong</surname><given-names>X.</given-names></name><name><surname>Lockey</surname><given-names>R.F.</given-names></name><name><surname>Mohapatra</surname><given-names>S.S.</given-names></name></person-group>
<article-title>Blocking intercellular adhesion molecule-1 on human epithelial cells decreases respiratory syncytial virus infection</article-title>
<source>Biochem. Biophys. Res. Commun.</source>
<year>2001</year>
<volume>280</volume>
<fpage>188</fpage>
<lpage>195</lpage>
<pub-id pub-id-type="doi">10.1006/bbrc.2000.4093</pub-id>
<?supplied-pmid 11162498?><pub-id pub-id-type="pmid">11162498</pub-id></element-citation></ref><ref id="B30-ijms-18-00556"><label>30.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marr</surname><given-names>N.</given-names></name><name><surname>Turvey</surname><given-names>S.E.</given-names></name></person-group>
<article-title>Role of human TLR4 in respiratory syncytial virus-induced NF-&#x003ba;B activation, viral entry and replication</article-title>
<source>Innate Immun.</source>
<year>2012</year>
<volume>18</volume>
<fpage>856</fpage>
<lpage>865</lpage>
<pub-id pub-id-type="doi">10.1177/1753425912444479</pub-id>
<?supplied-pmid 22535679?><pub-id pub-id-type="pmid">22535679</pub-id></element-citation></ref><ref id="B31-ijms-18-00556"><label>31.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Feldman</surname><given-names>S.A.</given-names></name><name><surname>Hendry</surname><given-names>R.M.</given-names></name><name><surname>Beeler</surname><given-names>J.A.</given-names></name></person-group>
<article-title>Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G</article-title>
<source>J. Virol.</source>
<year>1999</year>
<volume>73</volume>
<fpage>6610</fpage>
<lpage>6617</lpage>
<?supplied-pmid 10400758?><pub-id pub-id-type="pmid">10400758</pub-id></element-citation></ref><ref id="B32-ijms-18-00556"><label>32.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Malhotra</surname><given-names>R.</given-names></name><name><surname>Ward</surname><given-names>M.</given-names></name><name><surname>Bright</surname><given-names>H.</given-names></name><name><surname>Priest</surname><given-names>R.</given-names></name><name><surname>Foster</surname><given-names>M.R.</given-names></name><name><surname>Hurle</surname><given-names>M.</given-names></name><name><surname>Blair</surname><given-names>E.</given-names></name><name><surname>Bird</surname><given-names>M.</given-names></name></person-group>
<article-title>Isolation and characterisation of potential respiratory syncytial virus receptor(s) on epithelial cells</article-title>
<source>Microbes Infect.</source>
<year>2003</year>
<volume>5</volume>
<fpage>123</fpage>
<lpage>133</lpage>
<pub-id pub-id-type="doi">10.1016/S1286-4579(02)00079-5</pub-id>
<pub-id pub-id-type="pmid">12650770</pub-id></element-citation></ref><ref id="B33-ijms-18-00556"><label>33.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Araujo</surname><given-names>G.C.</given-names></name><name><surname>Silva</surname><given-names>R.H.</given-names></name><name><surname>Scott</surname><given-names>L.P.</given-names></name><name><surname>Araujo</surname><given-names>A.S.</given-names></name><name><surname>Souza</surname><given-names>F.P.</given-names></name><name><surname>de Oliveira</surname><given-names>R.J.</given-names></name></person-group>
<article-title>Structure and functional dynamics characterization of the ion channel of the human respiratory syncytial virus (HRSV) small hydrophobic protein (SH) transmembrane domain by combining molecular dynamics with excited normal modes</article-title>
<source>J. Mol. Model.</source>
<year>2016</year>
<volume>22</volume>
<fpage>286</fpage>
<pub-id pub-id-type="doi">10.1007/s00894-016-3150-6</pub-id>
<?supplied-pmid 27817112?><pub-id pub-id-type="pmid">27817112</pub-id></element-citation></ref><ref id="B34-ijms-18-00556"><label>34.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>B.</given-names></name><name><surname>Ma</surname><given-names>C.H.</given-names></name><name><surname>Brazas</surname><given-names>R.</given-names></name><name><surname>Jin</surname><given-names>H.</given-names></name></person-group>
<article-title>The major phosphorylation sites of the respiratory syncytial virus phosphoprotein are dispensable for virus replication in vitro</article-title>
<source>J. Virol.</source>
<year>2002</year>
<volume>76</volume>
<fpage>10776</fpage>
<lpage>10784</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.76.21.10776-10784.2002</pub-id>
<?supplied-pmid 12368320?><pub-id pub-id-type="pmid">12368320</pub-id></element-citation></ref><ref id="B35-ijms-18-00556"><label>35.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ouizougun-Oubari</surname><given-names>M.</given-names></name><name><surname>Pereira</surname><given-names>N.</given-names></name><name><surname>Tarus</surname><given-names>B.</given-names></name><name><surname>Galloux</surname><given-names>M.</given-names></name><name><surname>Lassoued</surname><given-names>S.</given-names></name><name><surname>Fix</surname><given-names>J.</given-names></name><name><surname>Tortorici</surname><given-names>M.A.</given-names></name><name><surname>Hoos</surname><given-names>S.</given-names></name><name><surname>Baron</surname><given-names>B.</given-names></name><name><surname>England</surname><given-names>P.</given-names></name><etal/></person-group>
<article-title>A druggable pocket at the nucleocapsid/phosphoprotein interaction site of human respiratory syncytial virus</article-title>
<source>J. Virol.</source>
<year>2015</year>
<volume>89</volume>
<fpage>11129</fpage>
<lpage>11143</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.01612-15</pub-id>
<?supplied-pmid 26246564?><pub-id pub-id-type="pmid">26246564</pub-id></element-citation></ref><ref id="B36-ijms-18-00556"><label>36.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tawar</surname><given-names>R.G.</given-names></name><name><surname>Duquerroy</surname><given-names>S.</given-names></name><name><surname>Vonrhein</surname><given-names>C.</given-names></name><name><surname>Varela</surname><given-names>P.F.</given-names></name><name><surname>Damier-Piolle</surname><given-names>L.</given-names></name><name><surname>Castagn&#x000e9;</surname><given-names>N.</given-names></name><name><surname>MacLellan</surname><given-names>K.</given-names></name><name><surname>Bedouelle</surname><given-names>H.</given-names></name><name><surname>Bricogne</surname><given-names>G.</given-names></name><name><surname>Bhella</surname><given-names>D.</given-names></name><etal/></person-group>
<article-title>Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus</article-title>
<source>Science</source>
<year>2009</year>
<volume>326</volume>
<fpage>1279</fpage>
<lpage>1283</lpage>
<pub-id pub-id-type="doi">10.1126/science.1177634</pub-id>
<?supplied-pmid 19965480?><pub-id pub-id-type="pmid">19965480</pub-id></element-citation></ref><ref id="B37-ijms-18-00556"><label>37.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fearns</surname><given-names>R.</given-names></name><name><surname>Collins</surname><given-names>P.L.</given-names></name></person-group>
<article-title>Role of the M2-1 transcription antitermination protein of respiratory syncytial virus in sequential transcription</article-title>
<source>J. Virol.</source>
<year>1999</year>
<volume>73</volume>
<fpage>5852</fpage>
<lpage>5864</lpage>
<?supplied-pmid 10364337?><pub-id pub-id-type="pmid">10364337</pub-id></element-citation></ref><ref id="B38-ijms-18-00556"><label>38.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bermingham</surname><given-names>A.</given-names></name><name><surname>Collins</surname><given-names>P.L.</given-names></name></person-group>
<article-title>The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between rna replication and transcription</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>1999</year>
<volume>96</volume>
<fpage>11259</fpage>
<lpage>11264</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.96.20.11259</pub-id>
<?supplied-pmid 10500164?><pub-id pub-id-type="pmid">10500164</pub-id></element-citation></ref><ref id="B39-ijms-18-00556"><label>39.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bendelja</surname><given-names>K.</given-names></name><name><surname>Gagro</surname><given-names>A.</given-names></name><name><surname>Bace</surname><given-names>A.</given-names></name><name><surname>Lokar-Kolbas</surname><given-names>R.</given-names></name><name><surname>Krsulovic-Hresic</surname><given-names>V.</given-names></name><name><surname>Drazenovic</surname><given-names>V.</given-names></name><name><surname>Mlinaric-Galinovic</surname><given-names>G.</given-names></name><name><surname>Rabatic</surname><given-names>S.</given-names></name></person-group>
<article-title>Predominant type-2 response in infants with respiratory syncytial virus (RSV) infection demonstrated by cytokine flow cytometry</article-title>
<source>Clin. Exp. Immunol.</source>
<year>2000</year>
<volume>121</volume>
<fpage>332</fpage>
<lpage>338</lpage>
<pub-id pub-id-type="doi">10.1046/j.1365-2249.2000.01297.x</pub-id>
<?supplied-pmid 10931150?><pub-id pub-id-type="pmid">10931150</pub-id></element-citation></ref><ref id="B40-ijms-18-00556"><label>40.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aoyagi</surname><given-names>M.</given-names></name><name><surname>Shimojo</surname><given-names>N.</given-names></name><name><surname>Sekine</surname><given-names>K.</given-names></name><name><surname>Nishimuta</surname><given-names>T.</given-names></name><name><surname>Kohno</surname><given-names>Y.</given-names></name></person-group>
<article-title>Respiratory syncytial virus infection suppresses IFN-&#x003b3; production of &#x003b3;&#x003b4; T cells</article-title>
<source>Clin. Exp. Immunol.</source>
<year>2003</year>
<volume>131</volume>
<fpage>312</fpage>
<lpage>317</lpage>
<pub-id pub-id-type="doi">10.1046/j.1365-2249.2003.02062.x</pub-id>
<?supplied-pmid 12562394?><pub-id pub-id-type="pmid">12562394</pub-id></element-citation></ref><ref id="B41-ijms-18-00556"><label>41.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pickles</surname><given-names>R.J.</given-names></name><name><surname>DeVincenzo</surname><given-names>J.P.</given-names></name></person-group>
<article-title>Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis</article-title>
<source>J. Pathol.</source>
<year>2015</year>
<volume>235</volume>
<fpage>266</fpage>
<lpage>276</lpage>
<pub-id pub-id-type="doi">10.1002/path.4462</pub-id>
<?supplied-pmid 25302625?><pub-id pub-id-type="pmid">25302625</pub-id></element-citation></ref><ref id="B42-ijms-18-00556"><label>42.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zeng</surname><given-names>R.</given-names></name><name><surname>Cui</surname><given-names>Y.</given-names></name><name><surname>Hai</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group>
<article-title>Pattern recognition receptors for respiratory syncytial virus infection and design of vaccines</article-title>
<source>Virus Res.</source>
<year>2012</year>
<volume>167</volume>
<fpage>138</fpage>
<lpage>145</lpage>
<pub-id pub-id-type="doi">10.1016/j.virusres.2012.06.003</pub-id>
<?supplied-pmid 22698878?><pub-id pub-id-type="pmid">22698878</pub-id></element-citation></ref><ref id="B43-ijms-18-00556"><label>43.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kurt-Jones</surname><given-names>E.A.</given-names></name><name><surname>Popova</surname><given-names>L.</given-names></name><name><surname>Kwinn</surname><given-names>L.</given-names></name><name><surname>Haynes</surname><given-names>L.M.</given-names></name><name><surname>Jones</surname><given-names>L.P.</given-names></name><name><surname>Tripp</surname><given-names>R.A.</given-names></name><name><surname>Walsh</surname><given-names>E.E.</given-names></name><name><surname>Freeman</surname><given-names>M.W.</given-names></name><name><surname>Golenbock</surname><given-names>D.T.</given-names></name><name><surname>Anderson</surname><given-names>L.J.</given-names></name><etal/></person-group>
<article-title>Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus</article-title>
<source>Nat. Immunol.</source>
<year>2000</year>
<volume>1</volume>
<fpage>398</fpage>
<lpage>401</lpage>
<pub-id pub-id-type="doi">10.1038/80833</pub-id>
<?supplied-pmid 11062499?><pub-id pub-id-type="pmid">11062499</pub-id></element-citation></ref><ref id="B44-ijms-18-00556"><label>44.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tayyari</surname><given-names>F.</given-names></name><name><surname>Marchant</surname><given-names>D.</given-names></name><name><surname>Moraes</surname><given-names>T.J.</given-names></name><name><surname>Duan</surname><given-names>W.</given-names></name><name><surname>Mastrangelo</surname><given-names>P.</given-names></name><name><surname>Hegele</surname><given-names>R.G.</given-names></name></person-group>
<article-title>Identification of nucleolin as a cellular receptor for human respiratory syncytial virus</article-title>
<source>Nat. Med.</source>
<year>2011</year>
<volume>17</volume>
<fpage>1132</fpage>
<lpage>1135</lpage>
<pub-id pub-id-type="doi">10.1038/nm.2444</pub-id>
<?supplied-pmid 21841784?><pub-id pub-id-type="pmid">21841784</pub-id></element-citation></ref><ref id="B45-ijms-18-00556"><label>45.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Triantafilou</surname><given-names>K.</given-names></name><name><surname>Kar</surname><given-names>S.</given-names></name><name><surname>Vakakis</surname><given-names>E.</given-names></name><name><surname>Kotecha</surname><given-names>S.</given-names></name><name><surname>Triantafilou</surname><given-names>M.</given-names></name></person-group>
<article-title>Human respiratory syncytial virus viroporin SH: A viral recognition pathway used by the host to signal inflammasome activation</article-title>
<source>Thorax</source>
<year>2013</year>
<volume>68</volume>
<fpage>66</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="doi">10.1136/thoraxjnl-2012-202182</pub-id>
<?supplied-pmid 23229815?><pub-id pub-id-type="pmid">23229815</pub-id></element-citation></ref><ref id="B46-ijms-18-00556"><label>46.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lifland</surname><given-names>A.W.</given-names></name><name><surname>Jung</surname><given-names>J.</given-names></name><name><surname>Alonas</surname><given-names>E.</given-names></name><name><surname>Zurla</surname><given-names>C.</given-names></name><name><surname>Crowe</surname><given-names>J.E.</given-names><suffix>Jr.</suffix></name><name><surname>Santangelo</surname><given-names>P.J.</given-names></name></person-group>
<article-title>Human respiratory syncytial virus nucleoprotein and inclusion bodies antagonize the innate immune response mediated by MDA5 and MAVS</article-title>
<source>J. Virol.</source>
<year>2012</year>
<volume>86</volume>
<fpage>8245</fpage>
<lpage>8258</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.00215-12</pub-id>
<?supplied-pmid 22623778?><pub-id pub-id-type="pmid">22623778</pub-id></element-citation></ref><ref id="B47-ijms-18-00556"><label>47.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kanneganti</surname><given-names>T.D.</given-names></name></person-group>
<article-title>Central roles of nlrs and inflammasomes in viral infection</article-title>
<source>Nat. Rev. Immunol.</source>
<year>2010</year>
<volume>10</volume>
<fpage>688</fpage>
<lpage>698</lpage>
<pub-id pub-id-type="doi">10.1038/nri2851</pub-id>
<?supplied-pmid 20847744?><pub-id pub-id-type="pmid">20847744</pub-id></element-citation></ref><ref id="B48-ijms-18-00556"><label>48.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Segovia</surname><given-names>J.</given-names></name><name><surname>Sabbah</surname><given-names>A.</given-names></name><name><surname>Mgbemena</surname><given-names>V.</given-names></name><name><surname>Tsai</surname><given-names>S.Y.</given-names></name><name><surname>Chang</surname><given-names>T.H.</given-names></name><name><surname>Berton</surname><given-names>M.T.</given-names></name><name><surname>Morris</surname><given-names>I.R.</given-names></name><name><surname>Allen</surname><given-names>I.C.</given-names></name><name><surname>Ting</surname><given-names>J.P.</given-names></name><name><surname>Bose</surname><given-names>S.</given-names></name></person-group>
<article-title>TLR2/MYD88/NF-&#x003ba;B pathway, reactive oxygen species, potassium efflux activates NLRP3/ASC inflammasome during respiratory syncytial virus infection</article-title>
<source>PLoS ONE</source>
<year>2012</year>
<volume>7</volume>
<elocation-id>e29695</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0029695</pub-id>
<?supplied-pmid 22295065?><pub-id pub-id-type="pmid">22295065</pub-id></element-citation></ref><ref id="B49-ijms-18-00556"><label>49.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bartz</surname><given-names>H.</given-names></name><name><surname>Buning-Pfaue</surname><given-names>F.</given-names></name><name><surname>Turkel</surname><given-names>O.</given-names></name><name><surname>Schauer</surname><given-names>U.</given-names></name></person-group>
<article-title>Respiratory syncytial virus induces prostaglandin E2, IL-10 and IL-11 generation in antigen presenting cells</article-title>
<source>Clin. Exp. Immunol.</source>
<year>2002</year>
<volume>129</volume>
<fpage>438</fpage>
<lpage>445</lpage>
<pub-id pub-id-type="doi">10.1046/j.1365-2249.2002.01927.x</pub-id>
<?supplied-pmid 12197884?><pub-id pub-id-type="pmid">12197884</pub-id></element-citation></ref><ref id="B50-ijms-18-00556"><label>50.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qiao</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>A.</given-names></name><name><surname>Jin</surname><given-names>X.</given-names></name></person-group>
<article-title>TSLP from RSV-stimulated rat airway epithelial cells activates myeloid dendritic cells</article-title>
<source>Immunol. Cell Biol.</source>
<year>2011</year>
<volume>89</volume>
<fpage>231</fpage>
<lpage>238</lpage>
<pub-id pub-id-type="doi">10.1038/icb.2010.85</pub-id>
<?supplied-pmid 20603637?><pub-id pub-id-type="pmid">20603637</pub-id></element-citation></ref><ref id="B51-ijms-18-00556"><label>51.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guerrero-Plata</surname><given-names>A.</given-names></name><name><surname>Casola</surname><given-names>A.</given-names></name><name><surname>Suarez</surname><given-names>G.</given-names></name><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Spetch</surname><given-names>L.</given-names></name><name><surname>Peeples</surname><given-names>M.E.</given-names></name><name><surname>Garofalo</surname><given-names>R.P.</given-names></name></person-group>
<article-title>Differential response of dendritic cells to human metapneumovirus and respiratory syncytial virus</article-title>
<source>Am. J. Respir. Cell Mol. Biol.</source>
<year>2006</year>
<volume>34</volume>
<fpage>320</fpage>
<lpage>329</lpage>
<pub-id pub-id-type="doi">10.1165/rcmb.2005-0287OC</pub-id>
<?supplied-pmid 16284360?><pub-id pub-id-type="pmid">16284360</pub-id></element-citation></ref><ref id="B52-ijms-18-00556"><label>52.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Qi</surname><given-names>F.</given-names></name><name><surname>Zeng</surname><given-names>S.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name></person-group>
<article-title>Natural helper cells contribute to pulmonary eosinophilia by producing IL-13 via IL-33/ST2 pathway in a murine model of respiratory syncytial virus infection</article-title>
<source>Int. Immunopharmacol.</source>
<year>2015</year>
<volume>28</volume>
<fpage>337</fpage>
<lpage>343</lpage>
<pub-id pub-id-type="doi">10.1016/j.intimp.2015.05.035</pub-id>
<?supplied-pmid 26044350?><pub-id pub-id-type="pmid">26044350</pub-id></element-citation></ref><ref id="B53-ijms-18-00556"><label>53.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zeng</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Qi</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name></person-group>
<article-title>IL-33 receptor (ST2) signalling is important for regulation of TH2-mediated airway inflammation in a murine model of acute respiratory syncytial virus infection</article-title>
<source>Scand. J. Immunol.</source>
<year>2015</year>
<volume>81</volume>
<fpage>494</fpage>
<lpage>501</lpage>
<pub-id pub-id-type="doi">10.1111/sji.12284</pub-id>
<?supplied-pmid 25721734?><pub-id pub-id-type="pmid">25721734</pub-id></element-citation></ref><ref id="B54-ijms-18-00556"><label>54.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>H.C.</given-names></name><name><surname>Headley</surname><given-names>M.B.</given-names></name><name><surname>Loo</surname><given-names>Y.M.</given-names></name><name><surname>Berlin</surname><given-names>A.</given-names></name><name><surname>Gale</surname><given-names>M.J.</given-names></name><name><surname>Debley</surname><given-names>J.S.</given-names></name><name><surname>Lukacs</surname><given-names>N.W.</given-names></name><name><surname>Ziegler</surname><given-names>S.F.</given-names></name></person-group>
<article-title>Thymic stromal lymphopoietin is induced by respiratory syncytial virus-infected airway epithelial cells and promotes a type 2 response to infection</article-title>
<source>J. Allergy Clin. Immunol.</source>
<year>2012</year>
<volume>130</volume>
<fpage>1187</fpage>
<lpage>1196</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaci.2012.07.031</pub-id>
<?supplied-pmid 22981788?><pub-id pub-id-type="pmid">22981788</pub-id></element-citation></ref><ref id="B55-ijms-18-00556"><label>55.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dakhama</surname><given-names>A.</given-names></name><name><surname>Park</surname><given-names>J.W.</given-names></name><name><surname>Taube</surname><given-names>C.</given-names></name><name><surname>Joetham</surname><given-names>A.</given-names></name><name><surname>Balhorn</surname><given-names>A.</given-names></name><name><surname>Miyahara</surname><given-names>N.</given-names></name><name><surname>Takeda</surname><given-names>K.</given-names></name><name><surname>Gelfand</surname><given-names>E.W.</given-names></name></person-group>
<article-title>The enhancement or prevention of airway hyperresponsiveness during reinfection with respiratory syncytial virus is critically dependent on the age at first infection and IL-13 production</article-title>
<source>J. Immunol.</source>
<year>2005</year>
<volume>175</volume>
<fpage>1876</fpage>
<lpage>1883</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.175.3.1876</pub-id>
<?supplied-pmid 16034131?><pub-id pub-id-type="pmid">16034131</pub-id></element-citation></ref><ref id="B56-ijms-18-00556"><label>56.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jeong</surname><given-names>K.I.</given-names></name><name><surname>Piepenhagen</surname><given-names>P.A.</given-names></name><name><surname>Kishko</surname><given-names>M.</given-names></name><name><surname>DiNapoli</surname><given-names>J.M.</given-names></name><name><surname>Groppo</surname><given-names>R.P.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Almond</surname><given-names>J.</given-names></name><name><surname>Kleanthous</surname><given-names>H.</given-names></name><name><surname>Delagrave</surname><given-names>S.</given-names></name><name><surname>Parrington</surname><given-names>M.</given-names></name></person-group>
<article-title>Cx3cr1 is expressed in differentiated human ciliated airway cells and co-localizes with respiratory syncytial virus on cilia in a G protein-dependent manner</article-title>
<source>PLoS ONE</source>
<year>2015</year>
<volume>10</volume>
<elocation-id>e0130517</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0130517</pub-id>
<?supplied-pmid 26107373?><pub-id pub-id-type="pmid">26107373</pub-id></element-citation></ref><ref id="B57-ijms-18-00556"><label>57.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kristjansson</surname><given-names>S.</given-names></name><name><surname>Bjarnarson</surname><given-names>S.P.</given-names></name><name><surname>Wennergren</surname><given-names>G.</given-names></name><name><surname>Palsdottir</surname><given-names>A.H.</given-names></name><name><surname>Arnadottir</surname><given-names>T.</given-names></name><name><surname>Haraldsson</surname><given-names>A.</given-names></name><name><surname>Jonsdottir</surname><given-names>I.</given-names></name></person-group>
<article-title>Respiratory syncytial virus and other respiratory viruses during the first 3 months of life promote a local TH2-like response</article-title>
<source>J. Allergy Clin. Immunol.</source>
<year>2005</year>
<volume>116</volume>
<fpage>805</fpage>
<lpage>811</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaci.2005.07.012</pub-id>
<?supplied-pmid 16210054?><pub-id pub-id-type="pmid">16210054</pub-id></element-citation></ref><ref id="B58-ijms-18-00556"><label>58.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Becker</surname><given-names>Y.</given-names></name></person-group>
<article-title>Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the TH1/TH2 cytokine balance toward increased levels of TH2 cytokines and ige, markers of allergy&#x02014;A review</article-title>
<source>Virus Genes</source>
<year>2006</year>
<volume>33</volume>
<fpage>235</fpage>
<lpage>252</lpage>
<?supplied-pmid 16972040?><pub-id pub-id-type="pmid">16972040</pub-id></element-citation></ref><ref id="B59-ijms-18-00556"><label>59.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stoppelenburg</surname><given-names>A.J.</given-names></name><name><surname>Salimi</surname><given-names>V.</given-names></name><name><surname>Hennus</surname><given-names>M.</given-names></name><name><surname>Plantinga</surname><given-names>M.</given-names></name><name><surname>Huis</surname><given-names>R.</given-names></name><name><surname>Walk</surname><given-names>J.</given-names></name><name><surname>Meerding</surname><given-names>J.</given-names></name><name><surname>Coenjaerts</surname><given-names>F.</given-names></name><name><surname>Bont</surname><given-names>L.</given-names></name><name><surname>Boes</surname><given-names>M.</given-names></name></person-group>
<article-title>Local IL-17a potentiates early neutrophil recruitment to the respiratory tract during severe RSV infection</article-title>
<source>PLoS ONE</source>
<year>2013</year>
<volume>8</volume>
<elocation-id>e78461</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0078461</pub-id>
<?supplied-pmid 24194936?><pub-id pub-id-type="pmid">24194936</pub-id></element-citation></ref><ref id="B60-ijms-18-00556"><label>60.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Faber</surname><given-names>T.E.</given-names></name><name><surname>Groen</surname><given-names>H.</given-names></name><name><surname>Welfing</surname><given-names>M.</given-names></name><name><surname>Jansen</surname><given-names>K.J.</given-names></name><name><surname>Bont</surname><given-names>L.J.</given-names></name></person-group>
<article-title>Specific increase in local IL-17 production during recovery from primary RSV bronchiolitis</article-title>
<source>J. Med. Virol.</source>
<year>2012</year>
<volume>84</volume>
<fpage>1084</fpage>
<lpage>1088</lpage>
<pub-id pub-id-type="doi">10.1002/jmv.23291</pub-id>
<?supplied-pmid 22585726?><pub-id pub-id-type="pmid">22585726</pub-id></element-citation></ref><ref id="B61-ijms-18-00556"><label>61.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saghafian-Hedengren</surname><given-names>S.</given-names></name><name><surname>Mathew</surname><given-names>J.L.</given-names></name><name><surname>Hagel</surname><given-names>E.</given-names></name><name><surname>Singhi</surname><given-names>S.</given-names></name><name><surname>Ray</surname><given-names>P.</given-names></name><name><surname>Ygberg</surname><given-names>S.</given-names></name><name><surname>Nilsson</surname><given-names>A.</given-names></name></person-group>
<article-title>Assessment of cytokine and chemokine signatures as potential biomarkers of childhood community-acquired pneumonia severity: A nested cohort study in India</article-title>
<source>Pediatr. Infect. Dis. J.</source>
<year>2017</year>
<volume>36</volume>
<fpage>102</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="doi">10.1097/INF.0000000000001364</pub-id>
<?supplied-pmid 27956727?><pub-id pub-id-type="pmid">27956727</pub-id></element-citation></ref><ref id="B62-ijms-18-00556"><label>62.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spann</surname><given-names>K.M.</given-names></name><name><surname>Tran</surname><given-names>K.C.</given-names></name><name><surname>Collins</surname><given-names>P.L.</given-names></name></person-group>
<article-title>Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-&#x003ba;B, and proinflammatory cytokines</article-title>
<source>J. Virol.</source>
<year>2005</year>
<volume>79</volume>
<fpage>5353</fpage>
<lpage>5362</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.79.9.5353-5362.2005</pub-id>
<?supplied-pmid 15827150?><pub-id pub-id-type="pmid">15827150</pub-id></element-citation></ref><ref id="B63-ijms-18-00556"><label>63.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wright</surname><given-names>P.F.</given-names></name><name><surname>Karron</surname><given-names>R.A.</given-names></name><name><surname>Madhi</surname><given-names>S.A.</given-names></name><name><surname>Treanor</surname><given-names>J.J.</given-names></name><name><surname>King</surname><given-names>J.C.</given-names></name><name><surname>O&#x02019;Shea</surname><given-names>A.</given-names></name><name><surname>Ikizler</surname><given-names>M.R.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Collins</surname><given-names>P.L.</given-names></name><name><surname>Cutland</surname><given-names>C.</given-names></name><etal/></person-group>
<article-title>The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans</article-title>
<source>J. Infect. Dis.</source>
<year>2006</year>
<volume>193</volume>
<fpage>573</fpage>
<lpage>581</lpage>
<pub-id pub-id-type="doi">10.1086/499600</pub-id>
<?supplied-pmid 16425137?><pub-id pub-id-type="pmid">16425137</pub-id></element-citation></ref><ref id="B64-ijms-18-00556"><label>64.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Munir</surname><given-names>S.</given-names></name><name><surname>le Nouen</surname><given-names>C.</given-names></name><name><surname>Luongo</surname><given-names>C.</given-names></name><name><surname>Buchholz</surname><given-names>U.J.</given-names></name><name><surname>Collins</surname><given-names>P.L.</given-names></name><name><surname>Bukreyev</surname><given-names>A.</given-names></name></person-group>
<article-title>Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells</article-title>
<source>J. Virol.</source>
<year>2008</year>
<volume>82</volume>
<fpage>8780</fpage>
<lpage>8796</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.00630-08</pub-id>
<?supplied-pmid 18562519?><pub-id pub-id-type="pmid">18562519</pub-id></element-citation></ref><ref id="B65-ijms-18-00556"><label>65.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Le Nou&#x000eb;n</surname><given-names>C.</given-names></name><name><surname>Munir</surname><given-names>S.</given-names></name><name><surname>Losq</surname><given-names>S.</given-names></name><name><surname>Winter</surname><given-names>C.C.</given-names></name><name><surname>McCarty</surname><given-names>T.</given-names></name><name><surname>Stephany</surname><given-names>D.A.</given-names></name><name><surname>Holmes</surname><given-names>K.L.</given-names></name><name><surname>Bukreyev</surname><given-names>A.</given-names></name><name><surname>Rabin</surname><given-names>R.L.</given-names></name><name><surname>Collins</surname><given-names>P.L.</given-names></name><etal/></person-group>
<article-title>Infection and maturation of monocyte-derived human dendritic cells by human respiratory syncytial virus, human metapneumovirus, and human parainfluenza virus type 3</article-title>
<source>Virology</source>
<year>2009</year>
<volume>385</volume>
<fpage>169</fpage>
<lpage>182</lpage>
<pub-id pub-id-type="doi">10.1016/j.virol.2008.11.043</pub-id>
<?supplied-pmid 19128816?><pub-id pub-id-type="pmid">19128816</pub-id></element-citation></ref><ref id="B66-ijms-18-00556"><label>66.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Tran</surname><given-names>K.C.</given-names></name><name><surname>Teng</surname><given-names>M.N.</given-names></name><name><surname>Heesom</surname><given-names>K.J.</given-names></name><name><surname>Matthews</surname><given-names>D.A.</given-names></name><name><surname>Barr</surname><given-names>J.N.</given-names></name><name><surname>Hiscox</surname><given-names>J.A.</given-names></name></person-group>
<article-title>The interactome of the human respiratory syncytial virus NS1 protein highlights multiple effects on host cell biology</article-title>
<source>J. Virol.</source>
<year>2012</year>
<volume>86</volume>
<fpage>7777</fpage>
<lpage>7789</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.00460-12</pub-id>
<?supplied-pmid 22593156?><pub-id pub-id-type="pmid">22593156</pub-id></element-citation></ref><ref id="B67-ijms-18-00556"><label>67.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>P.A.</given-names></name><name><surname>Bueno</surname><given-names>S.M.</given-names></name><name><surname>Riedel</surname><given-names>C.A.</given-names></name><name><surname>Kalergis</surname><given-names>A.M.</given-names></name></person-group>
<article-title>Impairment of T cell immunity by the respiratory syncytial virus: Targeting virulence mechanisms for therapy and prophylaxis</article-title>
<source>Curr. Med. Chem.</source>
<year>2009</year>
<volume>16</volume>
<fpage>4609</fpage>
<lpage>4625</lpage>
<pub-id pub-id-type="doi">10.2174/092986709789760724</pub-id>
<?supplied-pmid 19903147?><pub-id pub-id-type="pmid">19903147</pub-id></element-citation></ref><ref id="B68-ijms-18-00556"><label>68.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chang</surname><given-names>J.</given-names></name><name><surname>Braciale</surname><given-names>T.J.</given-names></name></person-group>
<article-title>Respiratory syncytial virus infection suppresses lung CD8<sup>+</sup> T cell effector activity and peripheral CD8<sup>+</sup> T cell memory in the respiratory tract</article-title>
<source>Nat. Med.</source>
<year>2002</year>
<volume>8</volume>
<fpage>54</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="doi">10.1038/nm0102-54</pub-id>
<?supplied-pmid 11786907?><pub-id pub-id-type="pmid">11786907</pub-id></element-citation></ref><ref id="B69-ijms-18-00556"><label>69.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>P.A.</given-names></name><name><surname>Prado</surname><given-names>C.E.</given-names></name><name><surname>Leiva</surname><given-names>E.D.</given-names></name><name><surname>Carreno</surname><given-names>L.J.</given-names></name><name><surname>Bueno</surname><given-names>S.M.</given-names></name><name><surname>Riedel</surname><given-names>C.A.</given-names></name><name><surname>Kalergis</surname><given-names>A.M.</given-names></name></person-group>
<article-title>Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>2008</year>
<volume>105</volume>
<fpage>14999</fpage>
<lpage>15004</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0802555105</pub-id>
<?supplied-pmid 18818306?><pub-id pub-id-type="pmid">18818306</pub-id></element-citation></ref><ref id="B70-ijms-18-00556"><label>70.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cespedes</surname><given-names>P.F.</given-names></name><name><surname>Bueno</surname><given-names>S.M.</given-names></name><name><surname>Ramirez</surname><given-names>B.A.</given-names></name><name><surname>Gomez</surname><given-names>R.S.</given-names></name><name><surname>Riquelme</surname><given-names>S.A.</given-names></name><name><surname>Palavecino</surname><given-names>C.E.</given-names></name><name><surname>Mackern-Oberti</surname><given-names>J.P.</given-names></name><name><surname>Mora</surname><given-names>J.E.</given-names></name><name><surname>Depoil</surname><given-names>D.</given-names></name><name><surname>Sacristan</surname><given-names>C.</given-names></name><etal/></person-group>
<article-title>Surface expression of the HRSV nucleoprotein impairs immunological synapse formation with T cells</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>2014</year>
<volume>111</volume>
<fpage>E3214</fpage>
<lpage>E3223</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1400760111</pub-id>
<?supplied-pmid 25056968?><pub-id pub-id-type="pmid">25056968</pub-id></element-citation></ref><ref id="B71-ijms-18-00556"><label>71.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bueno</surname><given-names>S.M.</given-names></name><name><surname>Gonzalez</surname><given-names>P.A.</given-names></name><name><surname>Cautivo</surname><given-names>K.M.</given-names></name><name><surname>Mora</surname><given-names>J.E.</given-names></name><name><surname>Leiva</surname><given-names>E.D.</given-names></name><name><surname>Tobar</surname><given-names>H.E.</given-names></name></person-group>
<article-title>Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>2008</year>
<volume>105</volume>
<fpage>20822</fpage>
<lpage>20827</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0806244105</pub-id>
<?supplied-pmid 19075247?><pub-id pub-id-type="pmid">19075247</pub-id></element-citation></ref><ref id="B72-ijms-18-00556"><label>72.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cherrie</surname><given-names>A.H.</given-names></name><name><surname>Anderson</surname><given-names>K.</given-names></name><name><surname>Wertz</surname><given-names>G.W.</given-names></name><name><surname>Openshaw</surname><given-names>P.J.</given-names></name></person-group>
<article-title>Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1B proteins of respiratory syncytial virus</article-title>
<source>J. Virol.</source>
<year>1992</year>
<volume>66</volume>
<fpage>2102</fpage>
<lpage>2110</lpage>
<?supplied-pmid 1548754?><pub-id pub-id-type="pmid">1548754</pub-id></element-citation></ref><ref id="B73-ijms-18-00556"><label>73.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bangham</surname><given-names>C.R.M.</given-names></name><name><surname>Openshaw</surname><given-names>P.J.M.</given-names></name><name><surname>Ball</surname><given-names>L.A.</given-names></name><name><surname>King</surname><given-names>A.M.Q.</given-names></name><name><surname>Wertz</surname><given-names>G.W.</given-names></name><name><surname>Askonas</surname><given-names>B.A.</given-names></name></person-group>
<article-title>Human and murine cytotoxic T cells specific to respiratory syncytial virus recognise the viral nucleoprotein (N) but not the major glycoprotein (G), expressed by vaccinia virus recombinants</article-title>
<source>J. Immunol.</source>
<year>1986</year>
<volume>137</volume>
<fpage>3973</fpage>
<lpage>3977</lpage>
<?supplied-pmid 2431051?><pub-id pub-id-type="pmid">2431051</pub-id></element-citation></ref><ref id="B74-ijms-18-00556"><label>74.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tregoning</surname><given-names>J.S.</given-names></name><name><surname>Yamaguchi</surname><given-names>Y.</given-names></name><name><surname>Harker</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Openshaw</surname><given-names>P.J.</given-names></name></person-group>
<article-title>The role of T cells in the enhancement of respiratory syncytial virus infection severity during adult reinfection of neonatally sensitized mice</article-title>
<source>J. Virol.</source>
<year>2008</year>
<volume>82</volume>
<fpage>4115</fpage>
<lpage>4124</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.02313-07</pub-id>
<?supplied-pmid 18272579?><pub-id pub-id-type="pmid">18272579</pub-id></element-citation></ref><ref id="B75-ijms-18-00556"><label>75.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>D.C.</given-names></name><name><surname>Harker</surname><given-names>J.A.</given-names></name><name><surname>Tregoning</surname><given-names>J.S.</given-names></name><name><surname>Atabani</surname><given-names>S.F.</given-names></name><name><surname>Johansson</surname><given-names>C.</given-names></name><name><surname>Schwarze</surname><given-names>J.</given-names></name><name><surname>Openshaw</surname><given-names>P.J.</given-names></name></person-group>
<article-title>CD25<sup>+</sup> natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection</article-title>
<source>J. Virol.</source>
<year>2010</year>
<volume>84</volume>
<fpage>8790</fpage>
<lpage>8798</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.00796-10</pub-id>
<?supplied-pmid 20573822?><pub-id pub-id-type="pmid">20573822</pub-id></element-citation></ref><ref id="B76-ijms-18-00556"><label>76.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Durant</surname><given-names>L.R.</given-names></name><name><surname>Makris</surname><given-names>S.</given-names></name><name><surname>Voorburg</surname><given-names>C.M.</given-names></name><name><surname>Loebbermann</surname><given-names>J.</given-names></name><name><surname>Johansson</surname><given-names>C.</given-names></name><name><surname>Openshaw</surname><given-names>P.J.</given-names></name></person-group>
<article-title>Regulatory T cells prevent TH2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice</article-title>
<source>J. Virol.</source>
<year>2013</year>
<volume>87</volume>
<fpage>10946</fpage>
<lpage>10954</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.01295-13</pub-id>
<?supplied-pmid 23926350?><pub-id pub-id-type="pmid">23926350</pub-id></element-citation></ref><ref id="B77-ijms-18-00556"><label>77.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Resch</surname><given-names>B.</given-names></name></person-group>
<article-title>Respiratory syncytial virus infection in high-risk infants&#x02014;An update on palivizumab prophylaxis</article-title>
<source>Open Microbiol. J.</source>
<year>2014</year>
<volume>8</volume>
<fpage>71</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="doi">10.2174/1874285801408010071</pub-id>
<?supplied-pmid 25132870?><pub-id pub-id-type="pmid">25132870</pub-id></element-citation></ref><ref id="B78-ijms-18-00556"><label>78.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>K.</given-names></name><name><surname>Incognito</surname><given-names>L.</given-names></name><name><surname>Cheng</surname><given-names>X.</given-names></name><name><surname>Ulbrandt</surname><given-names>N.D.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name></person-group>
<article-title>Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion</article-title>
<source>J. Virol.</source>
<year>2010</year>
<volume>84</volume>
<fpage>8132</fpage>
<lpage>8140</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.02699-09</pub-id>
<?supplied-pmid 20519399?><pub-id pub-id-type="pmid">20519399</pub-id></element-citation></ref><ref id="B79-ijms-18-00556"><label>79.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><collab>The IMpact-RSV Study Group</collab></person-group>
<article-title>Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants</article-title>
<source>Pediatrics</source>
<year>1998</year>
<volume>102</volume>
<fpage>531</fpage>
<lpage>537</lpage>
</element-citation></ref><ref id="B80-ijms-18-00556"><label>80.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ambrose</surname><given-names>C.S.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Kumar</surname><given-names>V.R.</given-names></name></person-group>
<article-title>A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children</article-title>
<source>Hum. Vaccin. Immunother.</source>
<year>2014</year>
<volume>10</volume>
<fpage>2785</fpage>
<lpage>2788</lpage>
<pub-id pub-id-type="doi">10.4161/hv.32082</pub-id>
<?supplied-pmid 25483483?><pub-id pub-id-type="pmid">25483483</pub-id></element-citation></ref><ref id="B81-ijms-18-00556"><label>81.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.J.</given-names></name><name><surname>Chan</surname><given-names>P.</given-names></name><name><surname>Paes</surname><given-names>B.</given-names></name><name><surname>Mitchell</surname><given-names>I.</given-names></name><name><surname>Li</surname><given-names>A.</given-names></name><name><surname>Lanct&#x000f4;t</surname><given-names>K.L.</given-names></name><collab>CARESS investigators</collab></person-group>
<article-title>Serious adverse events in the Canadian registry of children receiving palivizumab (CARESS) for respiratory syncytial virus prevention</article-title>
<source>PLoS ONE</source>
<year>2015</year>
<volume>10</volume>
<elocation-id>e0134711</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0134711</pub-id>
<?supplied-pmid 26237402?><pub-id pub-id-type="pmid">26237402</pub-id></element-citation></ref><ref id="B82-ijms-18-00556"><label>82.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Pfarr</surname><given-names>D.S.</given-names></name><name><surname>Tang</surname><given-names>Y.</given-names></name><name><surname>An</surname><given-names>L.L.</given-names></name><name><surname>Patel</surname><given-names>N.K.</given-names></name><name><surname>Watkins</surname><given-names>J.D.</given-names></name><name><surname>Huse</surname><given-names>W.D.</given-names></name><name><surname>Kiener</surname><given-names>P.A.</given-names></name><name><surname>Young</surname><given-names>J.F.</given-names></name></person-group>
<article-title>Ultra-potent antibodies against respiratory syncytial virus: Effects of binding kinetics and binding valence on viral neutralization</article-title>
<source>J. Mol. Biol.</source>
<year>2005</year>
<volume>350</volume>
<fpage>126</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="doi">10.1016/j.jmb.2005.04.049</pub-id>
<?supplied-pmid 15907931?><pub-id pub-id-type="pmid">15907931</pub-id></element-citation></ref><ref id="B83-ijms-18-00556"><label>83.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mej&#x000ed;as</surname><given-names>A.</given-names></name><name><surname>Ch&#x000e1;vez-Bueno</surname><given-names>S.</given-names></name><name><surname>R&#x000ed;os</surname><given-names>A.M.</given-names></name><name><surname>Aten</surname><given-names>M.F.</given-names></name><name><surname>Raynor</surname><given-names>B.</given-names></name><name><surname>Peromingo</surname><given-names>E.</given-names></name><name><surname>Soni</surname><given-names>P.</given-names></name><name><surname>Olsen</surname><given-names>K.D.</given-names></name><name><surname>Kiener</surname><given-names>P.A.</given-names></name><name><surname>G&#x000f3;mez</surname><given-names>A.M.</given-names></name><etal/></person-group>
<article-title>Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: Time versus potency</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>2005</year>
<volume>49</volume>
<fpage>4700</fpage>
<lpage>4707</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.49.11.4700-4707.2005</pub-id>
<?supplied-pmid 16251314?><pub-id pub-id-type="pmid">16251314</pub-id></element-citation></ref><ref id="B84-ijms-18-00556"><label>84.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carbonell-Estrany</surname><given-names>X.</given-names></name><name><surname>Sim&#x000f5;es</surname><given-names>E.A.</given-names></name><name><surname>Dagan</surname><given-names>R.</given-names></name><name><surname>Hall</surname><given-names>C.B.</given-names></name><name><surname>Harris</surname><given-names>B.</given-names></name><name><surname>Hultquist</surname><given-names>M.</given-names></name><name><surname>Connor</surname><given-names>E.M.</given-names></name><name><surname>Losonsky</surname><given-names>G.A.</given-names></name></person-group>
<article-title>Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: A noninferiority trial</article-title>
<source>Pediatrics.</source>
<year>2010</year>
<volume>125</volume>
<fpage>e35</fpage>
<lpage>e51</lpage>
<pub-id pub-id-type="doi">10.1542/peds.2008-1036</pub-id>
<?supplied-pmid 20008423?><pub-id pub-id-type="pmid">20008423</pub-id></element-citation></ref><ref id="B85-ijms-18-00556"><label>85.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fern&#x000e1;ndez</surname><given-names>P.</given-names></name><name><surname>Trenholme</surname><given-names>A.</given-names></name><name><surname>Abarca</surname><given-names>K.</given-names></name><name><surname>Griffin</surname><given-names>M.P.</given-names></name><name><surname>Hultquist</surname><given-names>M.</given-names></name><name><surname>Harris</surname><given-names>B.</given-names></name><name><surname>Losonsky</surname><given-names>G.A.</given-names></name></person-group>
<article-title>A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season</article-title>
<source>BMC Pediatr.</source>
<year>2010</year>
<volume>10</volume>
<elocation-id>38</elocation-id>
<pub-id pub-id-type="doi">10.1186/1471-2431-10-38</pub-id>
<?supplied-pmid 20525274?><pub-id pub-id-type="pmid">20525274</pub-id></element-citation></ref><ref id="B86-ijms-18-00556"><label>86.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lagos</surname><given-names>R.</given-names></name><name><surname>DeVincenzo</surname><given-names>J.P.</given-names></name><name><surname>Mu&#x000f1;oz</surname><given-names>A.</given-names></name><name><surname>Hultquist</surname><given-names>M.</given-names></name><name><surname>Suzich</surname><given-names>J.</given-names></name><name><surname>Connor</surname><given-names>E.M.</given-names></name><name><surname>Losonsky</surname><given-names>G.A.</given-names></name></person-group>
<article-title>Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children</article-title>
<source>Pediatr. Infect. Dis. J.</source>
<year>2009</year>
<volume>28</volume>
<fpage>835</fpage>
<lpage>837</lpage>
<pub-id pub-id-type="doi">10.1097/INF.0b013e3181a165e4</pub-id>
<?supplied-pmid 19636278?><pub-id pub-id-type="pmid">19636278</pub-id></element-citation></ref><ref id="B87-ijms-18-00556"><label>87.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ramilo</surname><given-names>O.</given-names></name><name><surname>Lagos</surname><given-names>R.</given-names></name><name><surname>S&#x000e1;ez-Llorens</surname><given-names>X.</given-names></name><name><surname>Suzich</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>C.K.</given-names></name><name><surname>Jensen</surname><given-names>K.M.</given-names></name><name><surname>Harris</surname><given-names>B.S.</given-names></name><name><surname>Losonsky</surname><given-names>G.A.</given-names></name><name><surname>Griffin</surname><given-names>M.P.</given-names></name></person-group>
<article-title>Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness</article-title>
<source>Pediatr. Infect. Dis. J.</source>
<year>2014</year>
<volume>33</volume>
<fpage>703</fpage>
<lpage>709</lpage>
<pub-id pub-id-type="doi">10.1097/INF.0000000000000240</pub-id>
<?supplied-pmid 24356256?><pub-id pub-id-type="pmid">24356256</pub-id></element-citation></ref><ref id="B88-ijms-18-00556"><label>88.</label><element-citation publication-type="gov">
<person-group person-group-type="author"><collab>Clinicaltrials.gob</collab></person-group>
<article-title>Nct00129766</article-title>
<comment>Avaliable online: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00129766">https://clinicaltrials.gov/ct2/show/NCT00129766</ext-link></comment>
<date-in-citation>(accessed on 28 February 2017)</date-in-citation>
</element-citation></ref><ref id="B89-ijms-18-00556"><label>89.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Robbie</surname><given-names>G.J.</given-names></name><name><surname>Criste</surname><given-names>R.</given-names></name><name><surname>Dall&#x02019;acqua</surname><given-names>W.F.</given-names></name><name><surname>Jensen</surname><given-names>K.</given-names></name><name><surname>Patel</surname><given-names>N.K.</given-names></name><name><surname>Losonsky</surname><given-names>G.A.</given-names></name><name><surname>Griffin</surname><given-names>M.P.</given-names></name></person-group>
<article-title>A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>2013</year>
<volume>57</volume>
<fpage>6147</fpage>
<lpage>6153</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.01285-13</pub-id>
<?supplied-pmid 24080653?><pub-id pub-id-type="pmid">24080653</pub-id></element-citation></ref><ref id="B90-ijms-18-00556"><label>90.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Griffin</surname><given-names>M.P.</given-names></name><name><surname>Khan</surname><given-names>A.A.</given-names></name><name><surname>Esser</surname><given-names>M.T.</given-names></name><name><surname>Jensen</surname><given-names>K.</given-names></name><name><surname>Takas</surname><given-names>T.</given-names></name><name><surname>Kankam</surname><given-names>M.K.</given-names></name><name><surname>Villafana</surname><given-names>T.</given-names></name><name><surname>Dubovsky</surname><given-names>F.</given-names></name></person-group>
<article-title>Safety, tolerability, and pharmacokinetics of the respiratory syncytial virus-prefusion F-targeting monoclonal antibody with an extended half-life, MEDI8897, in healthy adults</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>2016</year>
<pub-id pub-id-type="doi">10.1128/AAC.01714-16</pub-id>
<?supplied-pmid 27956428?><pub-id pub-id-type="pmid">27956428</pub-id></element-citation></ref><ref id="B91-ijms-18-00556"><label>91.</label><element-citation publication-type="gov">
<person-group person-group-type="author"><collab>Clinicaltrials.gob</collab></person-group>
<article-title>Nct02878330</article-title>
<comment>Avaliable online: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02878330">https://clinicaltrials.gov/ct2/show/NCT02878330</ext-link></comment>
<date-in-citation>(accessed on 28 February 2017)</date-in-citation>
</element-citation></ref><ref id="B92-ijms-18-00556"><label>92.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haynes</surname><given-names>L.M.</given-names></name><name><surname>Caidi</surname><given-names>H.</given-names></name><name><surname>Radu</surname><given-names>G.U.</given-names></name><name><surname>Miao</surname><given-names>C.</given-names></name><name><surname>Harcourt</surname><given-names>J.L.</given-names></name><name><surname>Tripp</surname><given-names>R.A.</given-names></name><name><surname>Anderson</surname><given-names>L.J.</given-names></name></person-group>
<article-title>Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice</article-title>
<source>J. Infect. Dis.</source>
<year>2009</year>
<volume>200</volume>
<fpage>439</fpage>
<lpage>447</lpage>
<pub-id pub-id-type="doi">10.1086/600108</pub-id>
<?supplied-pmid 19545210?><pub-id pub-id-type="pmid">19545210</pub-id></element-citation></ref><ref id="B93-ijms-18-00556"><label>93.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Han</surname><given-names>J.</given-names></name><name><surname>Takeda</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Zeng</surname><given-names>W.</given-names></name><name><surname>Jia</surname><given-names>Y.</given-names></name><name><surname>Shiraishi</surname><given-names>Y.</given-names></name><name><surname>Okamoto</surname><given-names>M.</given-names></name><name><surname>Dakhama</surname><given-names>A.</given-names></name><name><surname>Gelfand</surname><given-names>E.W.</given-names></name></person-group>
<article-title>Effects of anti-G and anti-F antibodies on airway function after respiratory syncytial virus infection</article-title>
<source>Am. J. Respir. Cell Mol. Biol.</source>
<year>2014</year>
<volume>51</volume>
<fpage>143</fpage>
<lpage>154</lpage>
<pub-id pub-id-type="doi">10.1165/rcmb.2013-0360OC</pub-id>
<pub-id pub-id-type="pmid">24521403</pub-id></element-citation></ref><ref id="B94-ijms-18-00556"><label>94.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Munoz</surname><given-names>F.M.</given-names></name><name><surname>Piedra</surname><given-names>P.A.</given-names></name><name><surname>Glezen</surname><given-names>W.P.</given-names></name></person-group>
<article-title>Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women</article-title>
<source>Vaccine</source>
<year>2003</year>
<volume>21</volume>
<fpage>3465</fpage>
<lpage>3467</lpage>
<pub-id pub-id-type="doi">10.1016/S0264-410X(03)00352-9</pub-id>
<pub-id pub-id-type="pmid">12850361</pub-id></element-citation></ref><ref id="B95-ijms-18-00556"><label>95.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blanco</surname><given-names>J.C.G.</given-names></name><name><surname>Pletneva</surname><given-names>L.M.</given-names></name><name><surname>Oue</surname><given-names>R.O.</given-names></name><name><surname>Patel</surname><given-names>M.C.</given-names></name><name><surname>Boukhvalovaa</surname><given-names>M.S.</given-names></name></person-group>
<article-title>Maternal transfer of RSV immunity in cotton rats vaccinated during pregnancy</article-title>
<source>Vaccine</source>
<year>2015</year>
<volume>33</volume>
<fpage>5371</fpage>
<lpage>5379</lpage>
<pub-id pub-id-type="doi">10.1016/j.vaccine.2015.08.071</pub-id>
<?supplied-pmid 26335771?><pub-id pub-id-type="pmid">26335771</pub-id></element-citation></ref><ref id="B96-ijms-18-00556"><label>96.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garg</surname><given-names>R.</given-names></name><name><surname>Latimer</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Simko</surname><given-names>E.</given-names></name><name><surname>Gerdts</surname><given-names>V.</given-names></name><name><surname>Potter</surname><given-names>A.</given-names></name></person-group>
<article-title>Maternal immunization with respiratory syncytial virus fusion protein formulated with a novel combination adjuvant provides protection from RSV in newborn lambs</article-title>
<source>Vaccine</source>
<year>2016</year>
<volume>34</volume>
<fpage>261</fpage>
<lpage>269</lpage>
<pub-id pub-id-type="doi">10.1016/j.vaccine.2015.11.029</pub-id>
<?supplied-pmid 26616551?><pub-id pub-id-type="pmid">26616551</pub-id></element-citation></ref><ref id="B97-ijms-18-00556"><label>97.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Glenn</surname><given-names>G.M.</given-names></name><name><surname>Fries</surname><given-names>L.F.</given-names></name><name><surname>Thomas</surname><given-names>D.N.</given-names></name><name><surname>Smith</surname><given-names>G.</given-names></name><name><surname>Kpamegan</surname><given-names>E.</given-names></name><name><surname>Lu</surname><given-names>H.</given-names></name><name><surname>Flyer</surname><given-names>D.</given-names></name><name><surname>Jani</surname><given-names>D.</given-names></name><name><surname>Hickman</surname><given-names>S.P.</given-names></name><name><surname>Piedra</surname><given-names>P.A.</given-names></name></person-group>
<article-title>A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age</article-title>
<source>J. Infect. Dis.</source>
<year>2016</year>
<volume>213</volume>
<fpage>411</fpage>
<lpage>422</lpage>
<pub-id pub-id-type="doi">10.1093/infdis/jiv406</pub-id>
<?supplied-pmid 26259809?><pub-id pub-id-type="pmid">26259809</pub-id></element-citation></ref><ref id="B98-ijms-18-00556"><label>98.</label><element-citation publication-type="gov">
<person-group person-group-type="author"><collab>Clinicaltrials.gob</collab></person-group>
<article-title>Nct02624947</article-title>
<comment>Avaliable online: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02624947">https://clinicaltrials.gov/ct2/show/NCT02624947</ext-link></comment>
<date-in-citation>(accessed on 28 February 2017)</date-in-citation>
</element-citation></ref><ref id="B99-ijms-18-00556"><label>99.</label><element-citation publication-type="webpage">
<person-group person-group-type="author"><collab>Clinicaltrials.gob</collab></person-group>
<article-title>Nct02608502</article-title>
<comment>Avaliable online: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02608502">https://clinicaltrials.gov/ct2/show/NCT02608502</ext-link></comment>
<date-in-citation>(accessed on 28 February 2017)</date-in-citation>
</element-citation></ref><ref id="B100-ijms-18-00556"><label>100.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kruijsen</surname><given-names>D.</given-names></name><name><surname>Schijf</surname><given-names>M.A.</given-names></name><name><surname>Lukens</surname><given-names>M.V.</given-names></name><name><surname>Uden</surname><given-names>N.O.V.</given-names></name><name><surname>Kimpen</surname><given-names>J.L.</given-names></name><name><surname>Coenjaerts</surname><given-names>F.E.</given-names></name><name><surname>Bleek</surname><given-names>G.M.V.</given-names></name></person-group>
<article-title>Local innate and adaptive immune responses regulate inflammatory cell influx into the lungs after vaccination with formalin inactivated RSV</article-title>
<source>Vaccine</source>
<year>2011</year>
<volume>29</volume>
<fpage>2730</fpage>
<lpage>2741</lpage>
<pub-id pub-id-type="doi">10.1016/j.vaccine.2011.01.087</pub-id>
<?supplied-pmid 21316502?><pub-id pub-id-type="pmid">21316502</pub-id></element-citation></ref><ref id="B101-ijms-18-00556"><label>101.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>H.W.</given-names></name><name><surname>Canchola</surname><given-names>J.G.</given-names></name><name><surname>Brandt</surname><given-names>C.D.</given-names></name><name><surname>Pyles</surname><given-names>G.</given-names></name><name><surname>Chanock</surname><given-names>R.M.</given-names></name><name><surname>Jensen</surname><given-names>K.</given-names></name><name><surname>Parrott</surname><given-names>R.H.</given-names></name></person-group>
<article-title>Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine</article-title>
<source>Am. J. Epidemiol.</source>
<year>1969</year>
<volume>89</volume>
<fpage>422</fpage>
<lpage>434</lpage>
<pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a120955</pub-id>
<?supplied-pmid 4305198?><pub-id pub-id-type="pmid">4305198</pub-id></element-citation></ref><ref id="B102-ijms-18-00556"><label>102.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kapikian</surname><given-names>A.Z.</given-names></name><name><surname>Mitchell</surname><given-names>R.H.</given-names></name><name><surname>Chanock</surname><given-names>R.M.</given-names></name><name><surname>Shvedoff</surname><given-names>R.A.</given-names></name><name><surname>Stewart</surname><given-names>C.E.</given-names></name></person-group>
<article-title>An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine</article-title>
<source>Am. J. Epidemiol.</source>
<year>1969</year>
<volume>89</volume>
<fpage>405</fpage>
<lpage>421</lpage>
<pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a120954</pub-id>
<?supplied-pmid 4305197?><pub-id pub-id-type="pmid">4305197</pub-id></element-citation></ref><ref id="B103-ijms-18-00556"><label>103.</label><element-citation publication-type="webpage">
<person-group person-group-type="author"><collab>PATH</collab></person-group>
<article-title>Respiratory Syncytial Virus. Vaccine Development against a Major Cause of Childhood Respiratory Illness</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://sites.Path.Org/vaccinedevelopment/respiratory-syncytial-virus-rsv">http://sites.Path.Org/vaccinedevelopment/respiratory-syncytial-virus-rsv</ext-link></comment>
<date-in-citation>(accessed on 17 Febreary 2017)</date-in-citation>
</element-citation></ref><ref id="B104-ijms-18-00556"><label>104.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hwang</surname><given-names>H.S.</given-names></name><name><surname>Kwon</surname><given-names>Y.M.</given-names></name><name><surname>Lee</surname><given-names>J.S.</given-names></name><name><surname>Yoo</surname><given-names>S.E.</given-names></name><name><surname>Lee</surname><given-names>Y.N.</given-names></name><name><surname>Ko</surname><given-names>E.J.</given-names></name><name><surname>Kim</surname><given-names>M.C.</given-names></name><name><surname>Cho</surname><given-names>M.K.</given-names></name><name><surname>Lee</surname><given-names>Y.T.</given-names></name><name><surname>Jung</surname><given-names>Y.J.</given-names></name><etal/></person-group>
<article-title>Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis</article-title>
<source>Antiviral Res.</source>
<year>2014</year>
<volume>110</volume>
<fpage>115</fpage>
<lpage>123</lpage>
<pub-id pub-id-type="doi">10.1016/j.antiviral.2014.07.016</pub-id>
<?supplied-pmid 25110201?><pub-id pub-id-type="pmid">25110201</pub-id></element-citation></ref><ref id="B105-ijms-18-00556"><label>105.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Ding</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name></person-group>
<article-title>Enhancement of mucosal and cellular immune response in mice by vaccination with respiratory syncytial virus DNA encapsulated with transfersome</article-title>
<source>Viral Immunol.</source>
<year>2008</year>
<volume>21</volume>
<fpage>483</fpage>
<lpage>490</lpage>
<pub-id pub-id-type="pmid">19115938</pub-id></element-citation></ref><ref id="B106-ijms-18-00556"><label>106.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liang</surname><given-names>B.</given-names></name><name><surname>Ngwuta</surname><given-names>J.O.</given-names></name><name><surname>Herbert</surname><given-names>R.</given-names></name><name><surname>Swerczek</surname><given-names>J.</given-names></name><name><surname>Dorward</surname><given-names>D.W.</given-names></name><name><surname>Amaro-Carambot</surname><given-names>E.</given-names></name><name><surname>Mackow</surname><given-names>N.</given-names></name><name><surname>Kabatova</surname><given-names>B.</given-names></name><name><surname>Lingemann</surname><given-names>M.</given-names></name><name><surname>Surman</surname><given-names>S.</given-names></name><etal/></person-group>
<article-title>Packaging and prefusion stabilization separately and additively increase the quantity and quality of respiratory syncytial virus (RSV)-neutralizing antibodies induced by an RSV fusion protein expressed by a parainfluenza virus vector</article-title>
<source>J. Virol.</source>
<year>2016</year>
<volume>90</volume>
<fpage>10022</fpage>
<lpage>10038</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.01196-16</pub-id>
<?supplied-pmid 27581977?><pub-id pub-id-type="pmid">27581977</pub-id></element-citation></ref><ref id="B107-ijms-18-00556"><label>107.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cautivo</surname><given-names>K.M.</given-names></name><name><surname>Bueno</surname><given-names>S.M.</given-names></name><name><surname>Cortes</surname><given-names>C.M.</given-names></name><name><surname>Wozniak</surname><given-names>A.</given-names></name><name><surname>Riedel</surname><given-names>C.A.</given-names></name><name><surname>Kalergis</surname><given-names>A.M.</given-names></name></person-group>
<article-title>Efficient lung recruitment of respiratory syncytial virusspecific TH1 cells induced by recombinant bacillus calmette-guerin promotes virus clearance and protects from infection</article-title>
<source>J. Immunol.</source>
<year>2010</year>
<volume>185</volume>
<fpage>7633</fpage>
<lpage>7645</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.0903452</pub-id>
<pub-id pub-id-type="pmid">21084664</pub-id></element-citation></ref><ref id="B108-ijms-18-00556"><label>108.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>C&#x000e9;spedes</surname><given-names>P.C.</given-names></name><name><surname>Rey-Jurado</surname><given-names>E.</given-names></name><name><surname>Espinoza</surname><given-names>J.A.</given-names></name><name><surname>Rivera</surname><given-names>C.A.</given-names></name><name><surname>Canedo-Marroqu&#x000ed;n</surname><given-names>G.</given-names></name><name><surname>Bueno</surname><given-names>S.M.</given-names></name><name><surname>Kalergis</surname><given-names>A.</given-names></name></person-group>
<article-title>A single, low dose of a CGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice</article-title>
<source>Vaccine</source>
<year>2016</year>
<pub-id pub-id-type="doi">10.1016/j.vaccine.2016.12.048</pub-id>
<?supplied-pmid 28065474?><pub-id pub-id-type="pmid">28065474</pub-id></element-citation></ref><ref id="B109-ijms-18-00556"><label>109.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Karron</surname><given-names>R.A.</given-names></name><name><surname>Luongo</surname><given-names>C.</given-names></name><name><surname>Thumar</surname><given-names>B.</given-names></name><name><surname>Loehr</surname><given-names>K.M.</given-names></name><name><surname>Englund</surname><given-names>J.A.</given-names></name><name><surname>Collins</surname><given-names>P.L.</given-names></name><name><surname>Buchholz</surname><given-names>U.J.</given-names></name></person-group>
<article-title>A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children</article-title>
<source>Sci. Transl. Med.</source>
<year>2015</year>
<volume>7</volume>
<fpage>175</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.aac8463</pub-id>
<?supplied-pmid 26537255?><pub-id pub-id-type="pmid">26537255</pub-id></element-citation></ref><ref id="B110-ijms-18-00556"><label>110.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Luongo</surname><given-names>C.</given-names></name><name><surname>Winter</surname><given-names>C.C.</given-names></name><name><surname>Collins</surname><given-names>P.L.</given-names></name><name><surname>Buchholz</surname><given-names>U.J.</given-names></name></person-group>
<article-title>Respiratory syncytial virus modified by deletions of the <italic>NS2</italic> gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature</article-title>
<source>J. Virol.</source>
<year>2013</year>
<volume>87</volume>
<fpage>1985</fpage>
<lpage>1996</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.02769-12</pub-id>
<pub-id pub-id-type="pmid">23236065</pub-id></element-citation></ref><ref id="B111-ijms-18-00556"><label>111.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jones</surname><given-names>B.G.</given-names></name><name><surname>Sealy</surname><given-names>R.E.</given-names></name><name><surname>Surman</surname><given-names>S.L.</given-names></name><name><surname>Portner</surname><given-names>A.</given-names></name><name><surname>Russell</surname><given-names>C.J.</given-names></name><name><surname>Slobod</surname><given-names>K.S.</given-names></name><name><surname>Dormitzer</surname><given-names>P.R.</given-names></name><name><surname>DeVincenzo</surname><given-names>J.</given-names></name><name><surname>Hurwitz</surname><given-names>J.L.</given-names></name></person-group>
<article-title>Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model</article-title>
<source>Vaccine</source>
<year>2014</year>
<volume>32</volume>
<fpage>3264</fpage>
<lpage>3273</lpage>
<pub-id pub-id-type="doi">10.1016/j.vaccine.2014.03.088</pub-id>
<?supplied-pmid 24721531?><pub-id pub-id-type="pmid">24721531</pub-id></element-citation></ref><ref id="B112-ijms-18-00556"><label>112.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Widjojoatmodjo</surname><given-names>M.N.</given-names></name><name><surname>Boes</surname><given-names>J.</given-names></name><name><surname>van Bers</surname><given-names>M.</given-names></name><name><surname>van Remmerden</surname><given-names>Y.</given-names></name><name><surname>Roholl</surname><given-names>P.J.</given-names></name><name><surname>Luytjes</surname><given-names>W.</given-names></name></person-group>
<article-title>A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats</article-title>
<source>Virol. J.</source>
<year>2010</year>
<volume>2</volume>
<fpage>114</fpage>
<pub-id pub-id-type="doi">10.1186/1743-422X-7-114</pub-id>
<?supplied-pmid 20525213?><pub-id pub-id-type="pmid">20525213</pub-id></element-citation></ref><ref id="B113-ijms-18-00556"><label>113.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lindell</surname><given-names>D.M.</given-names></name><name><surname>Morris</surname><given-names>S.B.</given-names></name><name><surname>White</surname><given-names>M.P.</given-names></name><name><surname>Kallal</surname><given-names>L.E.</given-names></name><name><surname>Lundy</surname><given-names>P.K.</given-names></name><name><surname>Hamouda</surname><given-names>T.</given-names></name><name><surname>Baker</surname><given-names>J.J.</given-names></name><name><surname>Lukacs</surname><given-names>N.W.</given-names></name></person-group>
<article-title>A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without TH2 associated vaccine-enhanced disease</article-title>
<source>PLoS ONE</source>
<year>2011</year>
<volume>6</volume>
<elocation-id>e21823</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0021823</pub-id>
<?supplied-pmid 21789184?><pub-id pub-id-type="pmid">21789184</pub-id></element-citation></ref><ref id="B114-ijms-18-00556"><label>114.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cimica</surname><given-names>V.</given-names></name><name><surname>Boigard</surname><given-names>H.</given-names></name><name><surname>Bhatia</surname><given-names>B.</given-names></name><name><surname>Fallon</surname><given-names>J.T.</given-names></name><name><surname>Alimova</surname><given-names>A.</given-names></name><name><surname>Gottlieb</surname><given-names>P.</given-names></name><name><surname>Galarza</surname><given-names>J.M.</given-names></name></person-group>
<article-title>Novel respiratory syncytial virus-like particle vaccine composed of the postfusion and prefusion conformations of the F glycoprotein</article-title>
<source>Clin. Vaccine Immunol.</source>
<year>2016</year>
<volume>23</volume>
<fpage>451</fpage>
<lpage>459</lpage>
<pub-id pub-id-type="doi">10.1128/CVI.00720-15</pub-id>
<?supplied-pmid 27030590?><pub-id pub-id-type="pmid">27030590</pub-id></element-citation></ref><ref id="B115-ijms-18-00556"><label>115.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>M.R.</given-names></name><name><surname>McGinnes-Cullen</surname><given-names>L.W.</given-names></name><name><surname>Kenward</surname><given-names>S.A.</given-names></name><name><surname>Willems</surname><given-names>K.N.</given-names></name><name><surname>Woodland</surname><given-names>R.T.</given-names></name><name><surname>Morrison</surname><given-names>T.G.</given-names></name></person-group>
<article-title>Modification of the respiratory syncytial virus F protein in virus-like particles impacts generation of B cell memory</article-title>
<source>J. Virol.</source>
<year>2014</year>
<volume>88</volume>
<fpage>10165</fpage>
<lpage>10176</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.01250-14</pub-id>
<?supplied-pmid 24965456?><pub-id pub-id-type="pmid">24965456</pub-id></element-citation></ref><ref id="B116-ijms-18-00556"><label>116.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Zhong</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Dong</surname><given-names>A.</given-names></name><name><surname>He</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name></person-group>
<article-title>A recombinant G protein plus cyclosporine A-based respiratory syncytial virus vaccine elicits humoral and regulatory T cell responses against infection without vaccine-enhanced disease</article-title>
<source>J. Immunol. February</source>
<year>2016</year>
<volume>196</volume>
<fpage>1721</fpage>
<lpage>1731</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.1502103</pub-id>
<?supplied-pmid 26792805?><pub-id pub-id-type="pmid">26792805</pub-id></element-citation></ref><ref id="B117-ijms-18-00556"><label>117.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krarup</surname><given-names>A.</given-names></name><name><surname>Truan</surname><given-names>D.</given-names></name><name><surname>Furmanova-Hollenstein</surname><given-names>P.</given-names></name><name><surname>Bogaert</surname><given-names>L.</given-names></name><name><surname>Bouchier</surname><given-names>P.</given-names></name><name><surname>Bisschop</surname><given-names>I.J.</given-names></name><name><surname>Widjojoatmodjo</surname><given-names>M.N.</given-names></name><name><surname>Zahn</surname><given-names>R.</given-names></name><name><surname>Schuitemaker</surname><given-names>H.</given-names></name><name><surname>McLellan</surname><given-names>J.S.</given-names></name><etal/></person-group>
<article-title>A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism</article-title>
<source>Nat. Commun.</source>
<year>2015</year>
<volume>3</volume>
<fpage>8143</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms9143</pub-id>
<?supplied-pmid 26333350?><pub-id pub-id-type="pmid">26333350</pub-id></element-citation></ref><ref id="B118-ijms-18-00556"><label>118.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rigter</surname><given-names>A.</given-names></name><name><surname>Widjaja</surname><given-names>I.</given-names></name><name><surname>Versantvoort</surname><given-names>H.</given-names></name><name><surname>Coenjaerts</surname><given-names>F.E.</given-names></name><name><surname>van Roosmalen</surname><given-names>M.</given-names></name><name><surname>Leenhouts</surname><given-names>K.</given-names></name><name><surname>Rottier</surname><given-names>P.J.</given-names></name><name><surname>Haijema</surname><given-names>B.J.</given-names></name><name><surname>de Haan</surname><given-names>C.A.</given-names></name></person-group>
<article-title>A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles</article-title>
<source>PLoS ONE</source>
<year>2013</year>
<volume>8</volume>
<elocation-id>e71072</elocation-id>
<pub-id pub-id-type="pmid">23951084</pub-id></element-citation></ref><ref id="B119-ijms-18-00556"><label>119.</label><element-citation publication-type="gov">
<person-group person-group-type="author"><collab>Clinicaltrials.gob</collab></person-group>
<article-title>Nct02958540</article-title>
<comment>Avaliable online: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02958540">https://clinicaltrials.gov/ct2/show/NCT02958540</ext-link></comment>
<date-in-citation>(accessed on 28 February 2017)</date-in-citation>
</element-citation></ref><ref id="B120-ijms-18-00556"><label>120.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Herv&#x000e9;</surname><given-names>P.L.</given-names></name><name><surname>Deloizy</surname><given-names>C.</given-names></name><name><surname>Descamps</surname><given-names>D.</given-names></name><name><surname>Rameix-Welti</surname><given-names>M.A.</given-names></name><name><surname>Fix</surname><given-names>J.</given-names></name><name><surname>McLellan</surname><given-names>J.S.</given-names></name><name><surname>El&#x000e9;ou&#x000eb;t</surname><given-names>J.F.</given-names></name><name><surname>Riffault</surname><given-names>S.</given-names></name></person-group>
<article-title>RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine</article-title>
<source>Nanomedicine</source>
<year>2016</year>
<volume>9634</volume>
<fpage>30114</fpage>
<lpage>30119</lpage>
<pub-id pub-id-type="doi">10.1016/j.nano.2016.08.006</pub-id>
<?supplied-pmid 27553073?><pub-id pub-id-type="pmid">27553073</pub-id></element-citation></ref><ref id="B121-ijms-18-00556"><label>121.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Herv&#x000e9;</surname><given-names>P.L.</given-names></name><name><surname>Descamps</surname><given-names>D.</given-names></name><name><surname>Deloizy</surname><given-names>C.</given-names></name><name><surname>Dhelft</surname><given-names>V.</given-names></name><name><surname>Laubreton</surname><given-names>D.</given-names></name><name><surname>Bouguyon</surname><given-names>E.</given-names></name><name><surname>Boukadiri</surname><given-names>A.</given-names></name><name><surname>Dubuquoy</surname><given-names>C.</given-names></name><name><surname>Larcher</surname><given-names>T.</given-names></name><name><surname>Benhamou</surname><given-names>P.H.</given-names></name><etal/></person-group>
<article-title>Non-invasive epicutaneous vaccine against respiratory syncytial virus: Preclinical proof of concept</article-title>
<source>J. Control. Release.</source>
<year>2016</year>
<volume>243</volume>
<fpage>146</fpage>
<lpage>159</lpage>
<pub-id pub-id-type="doi">10.1016/j.jconrel.2016.10.003</pub-id>
<?supplied-pmid 27720994?><pub-id pub-id-type="pmid">27720994</pub-id></element-citation></ref><ref id="B122-ijms-18-00556"><label>122.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Choi</surname><given-names>Y.</given-names></name><name><surname>Haynes</surname><given-names>L.M.</given-names></name><name><surname>Harcourt</surname><given-names>J.L.</given-names></name><name><surname>Anderson</surname><given-names>L.J.</given-names></name><name><surname>Jones</surname><given-names>L.P.</given-names></name><name><surname>Tripp</surname><given-names>R.A.</given-names></name></person-group>
<article-title>Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice</article-title>
<source>J. Virol.</source>
<year>2010</year>
<volume>84</volume>
<fpage>1148</fpage>
<lpage>1157</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.01755-09</pub-id>
<?supplied-pmid 19864390?><pub-id pub-id-type="pmid">19864390</pub-id></element-citation></ref><ref id="B123-ijms-18-00556"><label>123.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Palomo</surname><given-names>C.</given-names></name><name><surname>Mas</surname><given-names>V.</given-names></name><name><surname>Thom</surname><given-names>M.</given-names></name><name><surname>V&#x000e1;zquez</surname><given-names>M.</given-names></name><name><surname>Cano</surname><given-names>O.</given-names></name><name><surname>Terr&#x000f3;n</surname><given-names>M.C.</given-names></name><name><surname>Luque</surname><given-names>D.</given-names></name><name><surname>Taylor</surname><given-names>G.</given-names></name><name><surname>Melero</surname><given-names>J.A.</given-names></name></person-group>
<article-title>Influence of RSV F glycoprotein conformation on induction of protective immune responses</article-title>
<source>J. Virol.</source>
<year>2016</year>
<volume>90</volume>
<fpage>5485</fpage>
<lpage>5498</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.00338-16</pub-id>
<?supplied-pmid 27009962?><pub-id pub-id-type="pmid">27009962</pub-id></element-citation></ref><ref id="B124-ijms-18-00556"><label>124.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Langley</surname><given-names>J.M.</given-names></name><name><surname>Aggarwal</surname><given-names>N.</given-names></name><name><surname>Toma</surname><given-names>A.</given-names></name><name><surname>Halperin</surname><given-names>S.A.</given-names></name><name><surname>McNeil</surname><given-names>S.A.</given-names></name><name><surname>Fissette</surname><given-names>L.</given-names></name><name><surname>Dew&#x000e9;</surname><given-names>W.</given-names></name><name><surname>Leyssen</surname><given-names>M.</given-names></name><name><surname>Toussaint</surname><given-names>J.F.</given-names></name><name><surname>Dieussaert</surname><given-names>I.</given-names></name></person-group>
<article-title>A randomized, controlled, observer-blinded phase 1 study of the safety and immunogenicity of a respiratory syncytial virus vaccine with or without alum adjuvant</article-title>
<source>J. Infect. Dis.</source>
<year>2017</year>
<volume>215</volume>
<fpage>24</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="doi">10.1093/infdis/jiw453</pub-id>
<?supplied-pmid 27694633?><pub-id pub-id-type="pmid">27694633</pub-id></element-citation></ref><ref id="B125-ijms-18-00556"><label>125.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grunwald</surname><given-names>T.</given-names></name><name><surname>Tenbusch</surname><given-names>M.</given-names></name><name><surname>Schulte</surname><given-names>R.</given-names></name><name><surname>Raue</surname><given-names>K.</given-names></name><name><surname>Wolf</surname><given-names>H.</given-names></name><name><surname>Hannaman</surname><given-names>D.</given-names></name><name><surname>de Swart</surname><given-names>R.L.</given-names></name><name><surname>Uberla</surname><given-names>K.</given-names></name><name><surname>Stahl-Hennig</surname><given-names>C.</given-names></name></person-group>
<article-title>Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in nonhuman primatesj virol</article-title>
<source>J. Virol.</source>
<year>2014</year>
<volume>88</volume>
<fpage>3997</fpage>
<lpage>4007</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.02736-13</pub-id>
<?supplied-pmid 24453366?><pub-id pub-id-type="pmid">24453366</pub-id></element-citation></ref><ref id="B126-ijms-18-00556"><label>126.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shao</surname><given-names>H.Y.</given-names></name><name><surname>Hsu</surname><given-names>H.S.</given-names></name><name><surname>Yu</surname><given-names>S.L.</given-names></name><name><surname>Wu</surname><given-names>S.R.</given-names></name><name><surname>Hu</surname><given-names>K.C.</given-names></name><name><surname>Chang</surname><given-names>C.K.</given-names></name><name><surname>Liu</surname><given-names>C.C.</given-names></name><name><surname>Chow</surname><given-names>Y.H.</given-names></name></person-group>
<article-title>Immunogenicity of an adeno-vector vaccine expressing the F protein of a respiratory syncytial virus manufactured from serum-free suspension culture</article-title>
<source>Antiviral Res.</source>
<year>2016</year>
<volume>130</volume>
<fpage>27</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="doi">10.1016/j.antiviral.2016.03.011</pub-id>
<?supplied-pmid 27001351?><pub-id pub-id-type="pmid">27001351</pub-id></element-citation></ref><ref id="B127-ijms-18-00556"><label>127.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Widjojoatmodjo</surname><given-names>M.N.</given-names></name><name><surname>Bogaert</surname><given-names>L.</given-names></name><name><surname>Meek</surname><given-names>B.</given-names></name><name><surname>Zahn</surname><given-names>R.</given-names></name><name><surname>Vellinga</surname><given-names>J.</given-names></name><name><surname>Custers</surname><given-names>J.</given-names></name><name><surname>Serroyen</surname><given-names>J.</given-names></name><name><surname>Rado&#x00161;evi&#x00107;</surname><given-names>K.</given-names></name><name><surname>Schuitemaker</surname><given-names>H.</given-names></name></person-group>
<article-title>Recombinant low-seroprevalent adenoviral vectors AD26 and AD35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats</article-title>
<source>Vaccine</source>
<year>2015</year>
<volume>33</volume>
<fpage>5406</fpage>
<lpage>5414</lpage>
<pub-id pub-id-type="doi">10.1016/j.vaccine.2015.08.056</pub-id>
<?supplied-pmid 26319741?><pub-id pub-id-type="pmid">26319741</pub-id></element-citation></ref><ref id="B128-ijms-18-00556"><label>128.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>E.</given-names></name><name><surname>Okada</surname><given-names>K.</given-names></name><name><surname>Beeler</surname><given-names>J.A.</given-names></name><name><surname>Crim</surname><given-names>R.L.</given-names></name><name><surname>Piedra</surname><given-names>P.A.</given-names></name><name><surname>Gilbert</surname><given-names>B.E.</given-names></name><name><surname>Gambotto</surname><given-names>A.</given-names></name></person-group>
<article-title>Development of an adenovirus-based respiratory syncytial virus vaccine: Preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model</article-title>
<source>J. Virol.</source>
<year>2014</year>
<volume>88</volume>
<fpage>5100</fpage>
<lpage>5108</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.03194-13</pub-id>
<?supplied-pmid 24574396?><pub-id pub-id-type="pmid">24574396</pub-id></element-citation></ref><ref id="B129-ijms-18-00556"><label>129.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Waal</surname><given-names>L.</given-names></name><name><surname>Wyatt</surname><given-names>L.S.</given-names></name><name><surname>Y&#x000fc;ksel</surname><given-names>S.</given-names></name><name><surname>van Amerongen</surname><given-names>G.</given-names></name><name><surname>Moss</surname><given-names>B.</given-names></name><name><surname>Niesters</surname><given-names>H.G.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name><surname>de Swart</surname><given-names>R.L.</given-names></name></person-group>
<article-title>Vaccination of infant macaques with a recombinant modified vaccinia virus ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology</article-title>
<source>Vaccine</source>
<year>2004</year>
<volume>22</volume>
<fpage>923</fpage>
<lpage>926</lpage>
<pub-id pub-id-type="doi">10.1016/j.vaccine.2003.10.010</pub-id>
<?supplied-pmid 15161069?><pub-id pub-id-type="pmid">15161069</pub-id></element-citation></ref><ref id="B130-ijms-18-00556"><label>130.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Olszewska</surname><given-names>W.</given-names></name><name><surname>Suezer</surname><given-names>Y.</given-names></name><name><surname>Sutter</surname><given-names>G.</given-names></name><name><surname>Openshaw</surname><given-names>P.J.</given-names></name></person-group>
<article-title>Protective and disease-enhancing immune responses induced by recombinant modified vaccinia ankara (MVA) expressing respiratory syncytial virus proteins</article-title>
<source>Vaccine</source>
<year>2004</year>
<volume>23</volume>
<fpage>215</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="doi">10.1016/j.vaccine.2004.05.015</pub-id>
<?supplied-pmid 15531040?><pub-id pub-id-type="pmid">15531040</pub-id></element-citation></ref><ref id="B131-ijms-18-00556"><label>131.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Green</surname><given-names>C.A.</given-names></name><name><surname>Scarselli</surname><given-names>E.</given-names></name><name><surname>Voysey</surname><given-names>M.</given-names></name><name><surname>Capone</surname><given-names>S.</given-names></name><name><surname>Vitelli</surname><given-names>A.</given-names></name><name><surname>Nicosia</surname><given-names>A.</given-names></name><name><surname>Cortese</surname><given-names>R.</given-names></name><name><surname>Thompson</surname><given-names>A.J.</given-names></name><name><surname>de Lara</surname><given-names>C.</given-names></name><name><surname>Klenerman</surname><given-names>P.</given-names></name><etal/></person-group>
<article-title>Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults</article-title>
<source>BMJ Open</source>
<year>2015</year>
<volume>5</volume>
<fpage>e008748</fpage>
<?supplied-pmid 26510727?><pub-id pub-id-type="pmid">26510727</pub-id></element-citation></ref><ref id="B132-ijms-18-00556"><label>132.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Phan</surname><given-names>S.I.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>P.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Foster</surname><given-names>S.L.</given-names></name><name><surname>Teng</surname><given-names>M.N.</given-names></name><name><surname>Tripp</surname><given-names>R.A.</given-names></name><name><surname>Sakamoto</surname><given-names>K.</given-names></name><name><surname>He</surname><given-names>B.</given-names></name></person-group>
<article-title>A respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5)</article-title>
<source>Vaccine</source>
<year>2014</year>
<volume>32</volume>
<fpage>3050</fpage>
<lpage>3057</lpage>
<pub-id pub-id-type="doi">10.1016/j.vaccine.2014.03.049</pub-id>
<?supplied-pmid 24717150?><pub-id pub-id-type="pmid">24717150</pub-id></element-citation></ref><ref id="B133-ijms-18-00556"><label>133.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Teng</surname><given-names>M.N.</given-names></name><name><surname>Whitehead</surname><given-names>S.S.</given-names></name><name><surname>Bermingham</surname><given-names>A.</given-names></name><name><surname>St Claire</surname><given-names>M.</given-names></name><name><surname>Elkins</surname><given-names>W.R.</given-names></name><name><surname>Murphy</surname><given-names>B.R.</given-names></name><name><surname>Collins</surname><given-names>P.L.</given-names></name></person-group>
<article-title>Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees</article-title>
<source>J. Virol.</source>
<year>2000</year>
<volume>74</volume>
<fpage>9317</fpage>
<lpage>9321</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.74.19.9317-9321.2000</pub-id>
<?supplied-pmid 10982380?><pub-id pub-id-type="pmid">10982380</pub-id></element-citation></ref><ref id="B134-ijms-18-00556"><label>134.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stobart</surname><given-names>C.C.</given-names></name><name><surname>Rostad</surname><given-names>C.A.</given-names></name><name><surname>Ke</surname><given-names>Z.</given-names></name><name><surname>Dillard</surname><given-names>R.S.</given-names></name><name><surname>Hampton</surname><given-names>C.M.</given-names></name><name><surname>Strauss</surname><given-names>J.D.</given-names></name><name><surname>Yi</surname><given-names>H.</given-names></name><name><surname>Hotard</surname><given-names>A.L.</given-names></name><name><surname>Meng</surname><given-names>J.</given-names></name><name><surname>Pickles</surname><given-names>R.J.</given-names></name><etal/></person-group>
<article-title>A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation</article-title>
<source>Nat. Commun.</source>
<year>2016</year>
<volume>21</volume>
<fpage>13916</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms13916</pub-id>
<?supplied-pmid 28000669?><pub-id pub-id-type="pmid">28000669</pub-id></element-citation></ref><ref id="B135-ijms-18-00556"><label>135.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>D.I.</given-names></name><name><surname>Malkin</surname><given-names>E.</given-names></name><name><surname>Abughali</surname><given-names>N.</given-names></name><name><surname>Falloon</surname><given-names>J.</given-names></name><name><surname>Yi</surname><given-names>T.</given-names></name><name><surname>Dubovsky</surname><given-names>F.</given-names></name><collab>MI-CP149 Investigators</collab></person-group>
<article-title>Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children</article-title>
<source>Pediatr. Infect. Dis. J.</source>
<year>2012</year>
<volume>31</volume>
<fpage>109</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="doi">10.1097/INF.0b013e31823386f1</pub-id>
<?supplied-pmid 21926667?><pub-id pub-id-type="pmid">21926667</pub-id></element-citation></ref><ref id="B136-ijms-18-00556"><label>136.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liang</surname><given-names>B.</given-names></name><name><surname>Munir</surname><given-names>S.</given-names></name><name><surname>Amaro-Carambot</surname><given-names>E.</given-names></name><name><surname>Surman</surname><given-names>S.</given-names></name><name><surname>Mackow</surname><given-names>N.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Buchholz</surname><given-names>U.J.</given-names></name><name><surname>Collins</surname><given-names>P.L.</given-names></name><name><surname>Schaap-Nutt</surname><given-names>A.</given-names></name></person-group>
<article-title>Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: Effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection</article-title>
<source>J. Virol.</source>
<year>2014</year>
<volume>88</volume>
<fpage>4237</fpage>
<lpage>4250</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.03481-13</pub-id>
<?supplied-pmid 24478424?><pub-id pub-id-type="pmid">24478424</pub-id></element-citation></ref><ref id="B137-ijms-18-00556"><label>137.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>A.C.</given-names></name><name><surname>McAuliffe</surname><given-names>J.M.</given-names></name><name><surname>Murphy</surname><given-names>B.R.</given-names></name><name><surname>Collins</surname><given-names>P.L.</given-names></name></person-group>
<article-title>Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3</article-title>
<source>J. Virol.</source>
<year>2001</year>
<volume>75</volume>
<fpage>4594</fpage>
<lpage>4603</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.75.10.4594-4603.2001</pub-id>
<?supplied-pmid 11312329?><pub-id pub-id-type="pmid">11312329</pub-id></element-citation></ref><ref id="B138-ijms-18-00556"><label>138.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taylor</surname><given-names>G.</given-names></name><name><surname>Thom</surname><given-names>M.</given-names></name><name><surname>Capone</surname><given-names>S.</given-names></name><name><surname>Pierantoni</surname><given-names>A.</given-names></name><name><surname>Guzman</surname><given-names>E.</given-names></name><name><surname>Herbert</surname><given-names>R.</given-names></name><name><surname>Scarselli</surname><given-names>E.</given-names></name><name><surname>Napolitano</surname><given-names>F.</given-names></name><name><surname>Giuliani</surname><given-names>A.</given-names></name><name><surname>Folgori</surname><given-names>A.</given-names></name><etal/></person-group>
<article-title>Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections</article-title>
<source>Sci. Transl. Med.</source>
<year>2015</year>
<volume>7</volume>
<fpage>127</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.aac5757</pub-id>
<?supplied-pmid 26268314?><pub-id pub-id-type="pmid">26268314</pub-id></element-citation></ref><ref id="B139-ijms-18-00556"><label>139.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Qiao</surname><given-names>L.</given-names></name><name><surname>Hu</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Chai</surname><given-names>F.</given-names></name><name><surname>Pan</surname><given-names>Z.</given-names></name></person-group>
<article-title>Baculovirus vectors expressing F proteins in combination with virus-induced signaling adaptor (VISA) molecules confer protection against respiratory syncytial virus infection</article-title>
<source>Vaccine</source>
<year>2016</year>
<volume>34</volume>
<fpage>252</fpage>
<lpage>260</lpage>
<pub-id pub-id-type="doi">10.1016/j.vaccine.2015.11.027</pub-id>
<?supplied-pmid 26643933?><pub-id pub-id-type="pmid">26643933</pub-id></element-citation></ref><ref id="B140-ijms-18-00556"><label>140.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Chang</surname><given-names>J.</given-names></name></person-group>
<article-title>Baculovirus-based vaccine displaying respiratory syncytial virus glycoprotein induces protective immunity against RSV infection without vaccine-enhanced disease</article-title>
<source>Immun. Netw.</source>
<year>2012</year>
<volume>12</volume>
<fpage>8</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.4110/in.2012.12.1.8</pub-id>
<?supplied-pmid 22536165?><pub-id pub-id-type="pmid">22536165</pub-id></element-citation></ref><ref id="B141-ijms-18-00556"><label>141.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jones</surname><given-names>B.</given-names></name><name><surname>Zhan</surname><given-names>X.</given-names></name><name><surname>Mishin</surname><given-names>V.</given-names></name><name><surname>Slobod</surname><given-names>K.S.</given-names></name><name><surname>Surman</surname><given-names>S.</given-names></name><name><surname>Russell</surname><given-names>C.J.</given-names></name><name><surname>Portner</surname><given-names>A.</given-names></name><name><surname>Hurwitz</surname><given-names>J.L.</given-names></name></person-group>
<article-title>Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against HPIV-1, HPIV-2, HPIV-3, and RSV</article-title>
<source>Vaccine</source>
<year>2009</year>
<volume>27</volume>
<fpage>1848</fpage>
<lpage>1857</lpage>
<pub-id pub-id-type="doi">10.1016/j.vaccine.2009.01.041</pub-id>
<?supplied-pmid 19200447?><pub-id pub-id-type="pmid">19200447</pub-id></element-citation></ref><ref id="B142-ijms-18-00556"><label>142.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Green</surname><given-names>C.A.</given-names></name><name><surname>Scarselli</surname><given-names>E.</given-names></name><name><surname>Sande</surname><given-names>C.J.</given-names></name><name><surname>Thompson</surname><given-names>A.J.</given-names></name><name><surname>de Lara</surname><given-names>C.M.</given-names></name><name><surname>Taylor</surname><given-names>K.S.</given-names></name><name><surname>Haworth</surname><given-names>K.</given-names></name><name><surname>del Sorbo</surname><given-names>M.</given-names></name><name><surname>Angus</surname><given-names>B.</given-names></name><name><surname>Siani</surname><given-names>L.</given-names></name><etal/></person-group>
<article-title>Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults</article-title>
<source>Sci. Transl. Med.</source>
<year>2015</year>
<volume>7</volume>
<fpage>126</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.aac5745</pub-id>
<?supplied-pmid 26268313?><pub-id pub-id-type="pmid">26268313</pub-id></element-citation></ref><ref id="B143-ijms-18-00556"><label>143.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hwang</surname><given-names>H.S.</given-names></name><name><surname>Lee</surname><given-names>Y.T.</given-names></name><name><surname>Kim</surname><given-names>K.H.</given-names></name><name><surname>Park</surname><given-names>S.</given-names></name><name><surname>Kwon</surname><given-names>Y.M.</given-names></name><name><surname>Lee</surname><given-names>Y.</given-names></name><name><surname>Ko</surname><given-names>E.J.</given-names></name><name><surname>Jung</surname><given-names>Y.J.</given-names></name><name><surname>Lee</surname><given-names>J.S.</given-names></name><name><surname>Kim</surname><given-names>Y.J.</given-names></name><etal/></person-group>
<article-title>Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease</article-title>
<source>Virology</source>
<year>2016</year>
<volume>494</volume>
<fpage>215</fpage>
<lpage>224</lpage>
<pub-id pub-id-type="doi">10.1016/j.virol.2016.04.014</pub-id>
<?supplied-pmid 27123586?><pub-id pub-id-type="pmid">27123586</pub-id></element-citation></ref><ref id="B144-ijms-18-00556"><label>144.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schepens</surname><given-names>B.</given-names></name><name><surname>Sedeyn</surname><given-names>K.</given-names></name><name><surname>Vande Ginste</surname><given-names>L.</given-names></name><name><surname>de Baets</surname><given-names>S.</given-names></name><name><surname>Schotsaert</surname><given-names>M.</given-names></name><name><surname>Roose</surname><given-names>K.</given-names></name><name><surname>Houspie</surname><given-names>L.</given-names></name><name><surname>van Ranst</surname><given-names>M.</given-names></name><name><surname>Gilbert</surname><given-names>B.</given-names></name><name><surname>van Rooijen</surname><given-names>N.</given-names></name><etal/></person-group>
<article-title>Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein</article-title>
<source>EMBO Mol. Med.</source>
<year>2014</year>
<volume>6</volume>
<fpage>1436</fpage>
<lpage>1454</lpage>
<pub-id pub-id-type="doi">10.15252/emmm.201404005</pub-id>
<?supplied-pmid 25298406?><pub-id pub-id-type="pmid">25298406</pub-id></element-citation></ref><ref id="B145-ijms-18-00556"><label>145.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Langley</surname><given-names>J.</given-names></name><name><surname>Macdonald</surname><given-names>L.</given-names></name><name><surname>Weir</surname><given-names>G.</given-names></name><name><surname>Mackinnon-Cameron</surname><given-names>D.</given-names></name><name><surname>Lingyun Ye</surname><given-names>L.</given-names></name><name><surname>McNeil</surname><given-names>S.</given-names></name><name><surname>Schepens</surname><given-names>B.</given-names></name><name><surname>Saelens</surname><given-names>X.</given-names></name><name><surname>Stanford</surname><given-names>M.</given-names></name><name><surname>Scott Halperin</surname><given-names>S.</given-names></name></person-group>
<article-title>A phase I randomized, observer-blind, controlled, dose escalation trial of the safety and tolerability of two intramuscular doses of DPX-RSV(A), a respiratory syncytial virus (RSV) vaccine containing RSV SH antigen and a novel adjuvant depovax, or SH antigen co-administered with aluminum hydroxide, or placebo to healthy adults &#x02265;50&#x02013;64 years of age</article-title>
<source>Open Forum Infect. Dis.</source>
<year>2016</year>
<volume>3</volume>
<fpage>1270</fpage>
</element-citation></ref><ref id="B146-ijms-18-00556"><label>146.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheng</surname><given-names>W.</given-names></name></person-group>
<article-title>The density code for the development of a vaccine?</article-title>
<source>J. Pharm. Sci.</source>
<year>2016</year>
<volume>105</volume>
<fpage>3223</fpage>
<lpage>3232</lpage>
<pub-id pub-id-type="doi">10.1016/j.xphs.2016.07.020</pub-id>
<?supplied-pmid 27649885?><pub-id pub-id-type="pmid">27649885</pub-id></element-citation></ref><ref id="B147-ijms-18-00556"><label>147.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Glenn</surname><given-names>G.M.</given-names></name><name><surname>Smith</surname><given-names>G.</given-names></name><name><surname>Fries</surname><given-names>L.</given-names></name><name><surname>Raghunandan</surname><given-names>R.</given-names></name><name><surname>Lu</surname><given-names>H.</given-names></name><name><surname>Zhou</surname><given-names>B.</given-names></name><name><surname>Thomas</surname><given-names>D.N.</given-names></name><name><surname>Hickman</surname><given-names>S.P.</given-names></name><name><surname>Kpamegan</surname><given-names>E.</given-names></name><name><surname>Boddapati</surname><given-names>S.</given-names></name><etal/></person-group>
<article-title>Safety and immunogenicity of a SF9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine</article-title>
<source>Vaccine</source>
<year>2013</year>
<volume>31</volume>
<fpage>524</fpage>
<lpage>532</lpage>
<pub-id pub-id-type="doi">10.1016/j.vaccine.2012.11.009</pub-id>
<?supplied-pmid 23153449?><pub-id pub-id-type="pmid">23153449</pub-id></element-citation></ref><ref id="B148-ijms-18-00556"><label>148.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y.T.</given-names></name><name><surname>Ko</surname><given-names>E.J.</given-names></name><name><surname>Hwang</surname><given-names>H.S.</given-names></name><name><surname>Lee</surname><given-names>J.S.</given-names></name><name><surname>Kim</surname><given-names>K.H.</given-names></name><name><surname>Kwon</surname><given-names>Y.M.</given-names></name><name><surname>Kang</surname><given-names>S.M.</given-names></name></person-group>
<article-title>Respiratory syncytial virus-like nanoparticle vaccination induces long-term protection without pulmonary disease by modulating cytokines and T cells partially through alveolar macrophages</article-title>
<source>Int. J. Nanomed.</source>
<year>2015</year>
<volume>14</volume>
<fpage>4491</fpage>
<lpage>4505</lpage>
</element-citation></ref><ref id="B149-ijms-18-00556"><label>149.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Cummins</surname><given-names>C.</given-names></name><name><surname>Bayliss</surname><given-names>S.</given-names></name><name><surname>Sandercock</surname><given-names>J.</given-names></name><name><surname>Burls</surname><given-names>A.</given-names></name></person-group>
<article-title>Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children&#x02014;A systematic review and economic evaluation</article-title>
<source>Health Technol. Assess.</source>
<year>2008</year>
<volume>12</volume>
<fpage>1</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="doi">10.3310/hta12360</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig id="ijms-18-00556-f001" position="float"><label>Figure 1</label><caption><p>Mechanisms used by hRSV to evade host innate immunity. TLR, Toll-like receptor; RIG-I, retinoic acid-inducible gene-1; NOD, nucleotide-binding oligomerization domain; MDA5, melanoma differentiation-association gene 5; MAVS, mitochondrial antiviral signalling; NLPRP3, NOD-like receptor family pyrin domain containing 3; MyD88, Myeloid differentiation primary response gene 88; TIR, Toll-interleukin 1 receptor; TRAF, TNF receptor associated factor; IKK, Interleukin-1 receptor-associated kinase; IKK&#x003b2;, inhibitor of nuclear factor &#x003ba;B kinase subunit beta; IRF, Interferon regulatory factor. The human respiratory syncytial virus (hRSV) is recognized by different pattern recognition receptors (PRRs) including TLR-2, TLR-4, TLR-7, RIG-I and N&#x0039f;D2. hRSV can also enter via endocytosis and viral RNA can be recognized inside the endosome by TLR-7. Thereafter, a cascade of inflammatory response is activated. Different proteins of the hRSV have been found to interfere in the innate response against the infection. The nucleoprotein (N) has been suggested to &#x0201c;sequester&#x0201d; MDA5, RIG-I and MAVS proteins interfering in the type I IFN production. Besides from N, both non-structural (NS)1 and NS2 proteins have been shown to inhibit the IFN production at the MAVS and IRF3 level. On the other hand, the small hydrophobic (SH) protein has been shown to activate the NLPRP3 inflammasome, eventually triggering the production of IL-1&#x003b2; and IL-18.</p></caption><graphic xlink:href="ijms-18-00556-g001"/></fig><fig id="ijms-18-00556-f002" position="float"><label>Figure 2</label><caption><p>Airway inflammation due to hRSV infection. Upon hRSV infection, airway epithelial cells, dendritic cells and macrophages recognize hRSV. Such recognition triggers a downstream innate response, which eventually will result in the production of cytokines and chemokines such as thymic stromal lymphopoetin (TSLP), IL-13, IL-25, Il-10, IL-4, IL-5 and IL-6. Likewise, such hRSV infection promotes the recruitment of neutrophils, eosinophils and T cells. Such inflammatory response results in Th-2 and Th-7 response, mucus production and lung damage.</p></caption><graphic xlink:href="ijms-18-00556-g002"/></fig><table-wrap id="ijms-18-00556-t001" position="float"><object-id pub-id-type="pii">ijms-18-00556-t001_Table 1</object-id><label>Table 1</label><caption><p>Current research on therapies and vaccines against hRSV infection.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Strategy</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Preclinical/Clinical studies</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Motavizumab/MEDI-524</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-F Monoclonal antibody</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Better neutralizing activity than palivizumab. Phase I, II and III clinical studies show similar results to palivizumab and some adverse events.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B84-ijms-18-00556" ref-type="bibr">84</xref>,<xref rid="B85-ijms-18-00556" ref-type="bibr">85</xref>,<xref rid="B86-ijms-18-00556" ref-type="bibr">86</xref>,<xref rid="B87-ijms-18-00556" ref-type="bibr">87</xref>,<xref rid="B88-ijms-18-00556" ref-type="bibr">88</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Motavizumab/MEDI-8897</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-F Monoclonal antibody</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High levels of hRSV neutralizing antibodies. Phase I clinical studies show good tolerance and extended half-life of the antibody. Phase II in healthy preterm infants is ongoing.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B89-ijms-18-00556" ref-type="bibr">89</xref>,<xref rid="B90-ijms-18-00556" ref-type="bibr">90</xref>,<xref rid="B91-ijms-18-00556" ref-type="bibr">91</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mAb 131-2G</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti G Monoclonal antibody</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduces pulmonary inflammation in BABL/c mice.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B92-ijms-18-00556" ref-type="bibr">92</xref>,<xref rid="B93-ijms-18-00556" ref-type="bibr">93</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant F nanoparticle</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-F Polyclonal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Maternal immunization has been shown to protect lambs and cotton rat newborns. Immunogenic in healthy women of childbearing age (Phase I and II studies). Phase III in women in their third-trimester of pregnancy is ongoing and phase III is completed in older adults.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B95-ijms-18-00556" ref-type="bibr">95</xref>,<xref rid="B96-ijms-18-00556" ref-type="bibr">96</xref>,<xref rid="B97-ijms-18-00556" ref-type="bibr">97</xref>,<xref rid="B98-ijms-18-00556" ref-type="bibr">98</xref>,<xref rid="B99-ijms-18-00556" ref-type="bibr">99</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combination of RSV F VLP, G VLP, and RSV F DNA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RSV F DNA prime and VLPs containing F and G boost</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Induces hRSV F specific IgG2a antibodies, neutralizing antibodies and prevents lung disease in BALB/c mice.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B104-ijms-18-00556" ref-type="bibr">104</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SV pcD-F</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA vaccine encoding RSV-F protein</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Topical vaccine induces cellular and mucosal immune response and reduces cell infiltration to the lungs in BALB/c mice.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B105-ijms-18-00556" ref-type="bibr">105</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rB/HIPV3</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant parainfluenza virus (rB/HPIV3) expressing the G and F RSV proteins</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High quality hRSV-neutralizing antibodies in hamsters.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B106-ijms-18-00556" ref-type="bibr">106</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rBCG-N-hRSV</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BCG expressing N RSV protein</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protection against hRSV infection in mice with reduction of inflammation, hRSV specific T cell response and RSV antibodies in serum.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B71-ijms-18-00556" ref-type="bibr">71</xref>,<xref rid="B107-ijms-18-00556" ref-type="bibr">107</xref>,<xref rid="B108-ijms-18-00556" ref-type="bibr">108</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RSV LID &#x00394;M2-2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Live attenuated vaccine, M2-2 RSV protein deleted</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunogenic in chimpanzees. Phase I clinical study showed hRSV attenuation and RSV F serum IgG antibody responses.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B109-ijms-18-00556" ref-type="bibr">109</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RSV D46 cp&#x00394;M2-2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Live attenuated vaccine, M2-2 RSV protein deleted</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I in progress.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B103-ijms-18-00556" ref-type="bibr">103</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RSV Medi &#x00394;M2-2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Live attenuated vaccine, M2-2 RSV protein deleted</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I in progress.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B103-ijms-18-00556" ref-type="bibr">103</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RSV &#x00394;NS2 &#x00394;1313</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Live attenuated vaccine, NS2-2 RSV protein deleted</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Demonstrated a stable formulation. Phase I in progress.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B110-ijms-18-00556" ref-type="bibr">110</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RSV cps2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Attenuated cold-passaged respiratory syncytial virus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I in progress.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B103-ijms-18-00556" ref-type="bibr">103</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SeVRSV</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sendai virus (SeV)-based live intranasal vaccine that expresses the full length RSV fusion (F) gene</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protects cotton rats from hRSV challenge in a cotton rat maternal antibody model.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B111-ijms-18-00556" ref-type="bibr">111</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delta-G RSV</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant RSV lacking the G gene</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Induces long-lasting protection against hRSV challenge and resulted in no detectable replication of hRSV in lungs and nasal washes in cotton rats.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B112-ijms-18-00556" ref-type="bibr">112</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OE4</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Live attenuated vaccine, codon-reoptimization of RSV NS1, NS2 and G and deletion of SH proteins</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Proven stability and no enhanced disease in cotton rats and mice.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B100-ijms-18-00556" ref-type="bibr">100</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NE-RSV</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanoemulsion-inactivated RSV</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prevents hRSV-immunopathology and promotes Th-1/Th-17 responses in BALB/c mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B113-ijms-18-00556" ref-type="bibr">113</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VLPs F </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VLPs containing F RSV protein</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High levels of neutralizing antibodies, Th-1 mediated response and protects against lung hRSV infection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B114-ijms-18-00556" ref-type="bibr">114</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VLPs F and G</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VLPs containing F and G proteins</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protects against RSV disease by reducing cell infiltration to the lung, weight loss and lung damage.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B115-ijms-18-00556" ref-type="bibr">115</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPX-RSV-SH</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VLPs containing SH protein</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protection in cotton rats and mice. Phase I clinical trial showed safety.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B116-ijms-18-00556" ref-type="bibr">116</xref>,<xref rid="B117-ijms-18-00556" ref-type="bibr">117</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RSV BLP</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacterium-like particles (BLP)s containing F antigen</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protection in cotton rats and mice.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B118-ijms-18-00556" ref-type="bibr">118</xref>,<xref rid="B119-ijms-18-00556" ref-type="bibr">119</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N-FsII-nanorings</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanorings able to display the epitope of the human RSV F antigenic site</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protects against hRSV disease, however, they did not find detectable neutralizing antibodies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B120-ijms-18-00556" ref-type="bibr">120</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viaskin&#x000ae;-N</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patches loaded with N-nanorings</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protects against hRSV in pigs and is delivered efficiently through the skin and reaches Langerhans cells.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B121-ijms-18-00556" ref-type="bibr">121</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G+CSA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant G protein with cyclosporine A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Induces Treg cells, controlling the hRSV-immunopathology.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B116-ijms-18-00556" ref-type="bibr">116</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RSV F</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RSV fusion protein stabilized in the native prefusion conformation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Induces neutralizing antibodies and prevents viral challenge in cotton rats.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B117-ijms-18-00556" ref-type="bibr">117</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RSV G</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G protein polypeptide and peptide vaccination</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prevents hRSV pathology and inhibit hRSV replication in mice.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B122-ijms-18-00556" ref-type="bibr">122</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RSV F protein</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RSV postfusion F protein</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protection against hRSV challenge and antibody responses in BALB/c mice.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B123-ijms-18-00556" ref-type="bibr">123</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RSV-PreF</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RSV protein F vaccine engineered to maintain prefusion conformation.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hRSV neutralizing antibody responses in Phase I clinical trial.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B124-ijms-18-00556" ref-type="bibr">124</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA RSV</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA expressing soluble hRSV-F in combination with an AdV expressing the same antigen</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Systemic DNA prime-tonsillar booster immunization regimen and induces the recruitment of hRSV-F-specific T cells to and/or expansion of the T cells in the respiratory tract in non-human primates </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B125-ijms-18-00556" ref-type="bibr">125</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ad5.RSV-F</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adenovirus expressing F RSV protein</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunogenic in mice and cotton rats. Phase I currently in progress.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B126-ijms-18-00556" ref-type="bibr">126</xref>,<xref rid="B127-ijms-18-00556" ref-type="bibr">127</xref>,<xref rid="B128-ijms-18-00556" ref-type="bibr">128</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MVA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Modified vaccine Ankara virus expressing hRSV proteins</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protection in macaques. Safe and immunogenic in adults. Phase III currently in progress.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B129-ijms-18-00556" ref-type="bibr">129</xref>,<xref rid="B130-ijms-18-00556" ref-type="bibr">130</xref>,<xref rid="B131-ijms-18-00556" ref-type="bibr">131</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rPIV5-RSV-F and rPIV5-RSV-G</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccine based on Parainfluenza virus 5 (PIV5)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generation of serum neutralizing mice and no enhanced disease upon hRSV challenge in mice.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B132-ijms-18-00556" ref-type="bibr">132</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PanAd3-RSV</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccine based on Simian adenovirus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I clinical trial in progress.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B131-ijms-18-00556" ref-type="bibr">131</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>